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Chapter 1 
INTRODUCTION 
 
1.1. Stages of lung development 
 
 The mammalian lung development can be divided into several pre- and postnatal 
phases (Figure 1) [29, 56]. In rodents it starts around 9
th
 gestational day and in humans at 
the 4
th
 gestational week (embryonic stage). During this stage the trachea is formed from the 
foregut lung bud and separated from the esophagus. The distal part of the tracheal bud starts 
to form two primary bronchial buds of the future right and left main bronchi. The 
Pseudoglandular stage starts around 12
th
 gestational day in rodents and around the 8
th
 
gestational week in human. During this time the bronchi develop into secondary (lobar 
bronchi) and tertiary bronchi (segmental bronchi). Along with the branching of the airways, 
endodermal- and mesodermal-derived cells start to appear [56]. These endodermal derived 
cells include neuroendocrine cells, basal cells, and ciliated/secretory cells (clara/goblet 
cells) [92]. Whereas mesodermal derived cells include: smooth muscle cells, fibroblasts and 
cells forming cartilage of the bigger airways [29, 92]. The next canalicular stage starts 
about 16.5
th
 gestational day in rodents and at the 16
th
 gestational week in humans. The 
terminal bronchioles start to form respiratory bronchioles and alveolar ducts lined by 
nonciliated epithelial cells [56]. Vascularization and capillarization also begins at this stage 
[29, 92]. The most important respiratory system structure establishes about 5
th
 postnatal day 
in rodents and at the 36
th
 gestational week in humans during the terminal saccular stage 
[56]. At this stage the primitive alveoli are formed. The respiratory epithelium and the 
endothelium as well as fibroblasts interact to give rise to the morphological area of the gas 
exchange region. At the same time alveolar epithelial type II cells starts to secret 
pulmonary surfactant, which reduces the lung surface tension [29, 56]. In rodents, the 
alveolar stage takes place after birth, whereas in humans, fully functional alveoli start to 
develop before birth. During alveolarization, the terminal saccules and alveolar ducts 
increase in number and the saccular walls are divided by primary septa. The newly formed 
Introduction 
2 
 
alveoli are the most important units of gas exchange in mammals [19]. The stage of 
alveolarization lasts up to postnatal day 30 in rodents and up to two years of age in humans. 
However further secondary septa formation may still be continued [19, 56, 92, 106]. Since 
the objective of this current work is to understand the late lung development processes of 
alveolarization and septation, these processes are discussed in detail in the next section. 
 
Figure 1 Comparison of human and mouse lung development stages timing. Arrows indicate the 
duration of the process of alveolarization. Modified according to [56]. 
   
1.2. Alveolarization 
 
The central layer of connective tissue “sandwiched” between two capillary networks 
(primary septum) represents the basic structure necessary for alveolarization [19]. During 
the process of alveolarization, the gas-exchange area is enlarged by subdivision of the 
terminal sacs (septation). The outgrowth of the secondary septum from the primary septum 
leads to the formation of new interalveolar walls. Elastic fibers of the connective tissue 
produced by fibroblasts and the reorganization of the capillary network contribute to these 
key structural changes. A large number of new bulges elongate and form secondary septa 
with the double capillary network outlining the future alveoli (Figure 2) [19, 103]. This 
process of “bulk alveolarization” is terminated at about 2 weeks after birth in rodents and 
12–24 months in humans. The last stage of lung development, the microvascular maturation 
starts at postnatal day 14 (P14) and lasts until P30 in rodents. In humans it starts several 
months after birth and may last till 2-3 years, even 8 years of age [19]. At this stage the 
alveolar septum double capillary layer is transformed into a single-layered capillary 
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network [15, 19, 103] and the absolute mass of the intercalated septal interstitium is 
reduced [19, 98, 103].  
Gas exchange occurs across the mature alveolar septum between the finest barriers 
of type I epithelial cells, the basement membrane (specialized form of extracellular matrix) 
and endothelial cells of the capillaries [4, 19]. The anatomical structures of gas exchange 
are so-called alveoli, which are lined by respiratory epithelium and wrapped in a fine mesh 
of capillaries covering about 70% of its area. Septation process depends on mechanical 
forces produced by elastin and collagen fibers. These fibers form extracellular matrix 
(ECM) and are produced by mesenchymal fibroblasts. Fibroblasts carry out certain function 
during alveolar septation and their dysfunction might be a cause of many lung diseases [4]. 
 
 
Figure 2 Formation of new septa and new alveoli. Accumulated at the tip of new septa elastin and 
collagen fibers produce forces that push the tissue into the saccular airspace where alveolar sacs 
are subdivided into definitive alveoli (secondary septation). The immature septa (primary and 
secondary) contain double capillary network, which becomes single capillary network during the 
microvascular maturation, moreover the interstitium (connective tissue) thinning occurs. 
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1.3. Lung interstitial fibroblasts 
 
 Previous multiple works have evidenced that there are three distinguished 
heterogeneous fibroblast subsets present in lung [67, 79, 81, 94]. These fibroblasts subsets 
are:  
 Lipofibroblasts,  
 Myofibroblasts and  
 Platelet-derived growth factor receptor alpha (PDGFRα)-positive cells.  
It is known that the fibroblast subpopulations are able to transdifferentiate to each other 
[57]. Each of this fibroblast subset plays an essential role during lung development and 
pulmonary diseases. They can be characterized by specific cytoskeletal or surface markers 
as well as a spatial and temporal appearance pattern in lung tissue. 
 
1.3.1. The lipofibroblast 
 
Morphology and phenotype:  
In the immature rodent lung, the lipid-containing interstitial cells consist for about 
50% of the resident alveolar wall cells [94]. Lipofibroblasts are interstitial mesenchymal 
cells which are characterized mainly by lipid droplets content. These cells were described 
in the early 1970s in the fetal and neonatal rat lung [88]. In early 1980s they were called 
lipid interstitial cells (or lipid droplet–laden), ipso facto distinguishing them from non-lipid 
interstitial cells (NLIC). Lipofibroblasts have characteristics similar to other mesenchymal 
cells, such as adipocytes, pericytes or smooth muscle cells. However, they contain more 
glycogen and are localized to the central region of the alveolar septum. Lipofibroblasts 
contain intermediate contractile filaments similar to those observed in contractile 
myofibroblasts or contractile interstitial cells (CIC). In contrast to the NLICs, 
lipofibroblasts are Thy-1-positive (Thy-1
+
) [81]. Thy-1 is a glycosylphosphatidylinositol-
linked cell-surface glycoprotein discovered on T lymphocyte surface and involved in 
transmembrane signal transduction. Thy-1 plays a role in lipofibroblast differentiation and 
also influences the regulation of lipid homeostasis via peroxisome proliferator-activated 
receptor-γ (PPARγ) activity [81, 119]. PPARγ is a nuclear transcription factor which seems 
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to play an essential role during fibroblast differentiation into lipogenic phenotype and 
prevents interstitial fibroblast to myofibroblast differentiation [94]. Thy-1
+
 and Thy-1
-
 
subsets of lung fibroblast differ morphologically when cultured in vitro. Thy-1
+
 fibroblasts 
are more elongated, spindle-shaped, and have filopodia which suggest their contractile 
function, whereas the Thy-1
-
 cells are more round, spread and lack filopodia [81, 119]. On 
the other hand only Thy-1
-
, but not Thy-1
+
 human orbital fibroblasts differentiate into 
lipofibroblasts when stimulated with a PPARγ agonist, such as prostaglandin J2 [58]. 
 In rodents, the lipofibroblasts are detectable in a large amount at gestational day 16. 
In the second neonatal week, their number decreases due to apoptosis and reduced 
proliferation [81, 98]. Lipofibroblasts are also observed in adult rats and mice lungs, 
although they contain much less lipids than in the neonate. In the neonate rat lung 
approximately 85% of the lipid-laden cells constitute of lipofibroblasts, whereas the 
remaining 15% constitutes of macrophages. Lipofibroblasts and the non-lipid interstitial 
cells exhibit similar ECM and cytoskeletal proteins profile in cell culture [81]. 
 
Function: 
 It has been shown that lipofibroblasts are the essential cells assisting pulmonary 
surfactant production and epithelial cell differentiation into alveolar type II cells. Thus they 
play a critical role during normal lung development, homeostasis, and later adult lung 
injury and repair [81, 94]. Lipofibroblasts provide high levels of triglycerides to the 
neighboring type II cells which are necessary for phospholipid synthesis (main component 
of surfactant) in their surfactant-secretory granules, so-called lamellar bodies [81]. The 
highest accumulation of triglycerides in rodent pulmonary fibroblasts occurs just before 
birth. Lipofibroblast and alveolar type II cell interaction is facilitated by a specific 
molecule, the parathyroid hormone-related protein (PTHrP). It is secreted by alveolar type 
II cells and subsequently binds to the PTHrP receptor on lipofibroblasts. PTHrP/ PTHrP 
receptor signaling pathway stimulates lipofibroblast differentiation by down-regulating the 
Wnt signaling pathway. Moreover leptin which is secreted by lipofibroblasts binds to its 
receptor on the alveolar type II cells and facilitates the mesenchymal-epithelial cross talk 
[113]. Epithelial-mesenchymal interaction up-regulates PPARγ and its downstream target 
adipose differentiation-related protein (ADRP). The ADRP is a lipid storage droplet-
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coating protein that facilitates triglyceride uptake by lipofibroblast and alveolar type II cells 
[74, 94, 104, 119].  
 Lipofibroblasts are also the source for retinol and retinoic acid (RA), the 
biologically active forms of retinoids outside the retina. RA is involved in the regulation of 
gene expression during early postnatal lung development. Lipofibroblast nuclear receptor, 
the PPAR-γ forms heterodimer with the retinoid-X receptor (RXR), and binds to responsive 
elements in the regulatory regions of target genes. The heterodimer might be accelerated by 
prostaglandins secreted by alveolar type II cells [81].  
 
1.3.2. The myofibroblast 
 
 Myofibroblasts are a differentiated type of interstitial fibroblasts responsible for 
wound healing and organs remodeling. They fulfill two major functions in the lung: 
extracellular matrix (ECM) synthesis and fibers-related tension production [67]. Boström, 
et al. showed that lung alveolar myofibroblasts are critical for the formation of secondary 
septa, and their absence is associated with a lack of functional alveoli [14]. 
 
Morphology and phenotype:  
In normal conditions pulmonary myofibroblasts exhibit phenotype with few actin-
associated cell-cell and cell-matrix interactions and a little ECM production. Activated 
myofibroblasts migrate and acquire contractile phenotype. The key factors responsible for 
fibroblasts differentiation are cytokines and growth factors released by inflammatory cells 
and residing epithelial cells. Furthermore, changes in the mechanical microenvironment 
(eg. extracellular stress) of the lung can also influence myofibroblast differentiation [47, 
48]. Differentiated myofibroblasts are characterized by de novo expression of α-smooth 
muscle actin (α-SMA). α-SMA represents the stress fiber which is connected with the ECM 
at the sites of supermature focal adhesions and with cells via adherent junctions. α-SMA is 
encoded by the Acta gene and its regulation is complex and depends on a variety of factors. 
Pro-fibrotic cytokines, transcription factors, mechanical forces and stiff ECM with its 
specialized proteins like the ED-A splice variant of fibronectin are involved in Acta gene 
regulation. α-SMA is activated by TGFβ, whose signaling is modulated by SMAD3 [47, 
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48]. Platelet-derived growth factor (PDGF) initiates chemoattraction and differentiation of 
these cells. Fibroblast growth factor (FGF) directly orchestrates cell proliferation, whereas 
indirectly effects the alpha and beta transforming growth factors (TGFα, TGFβ) [67].  
Lung alveolar myofibroblasts are characterized by the expression of intermediate 
filaments, i.e. vimentin which stabilizes cellular architecture, α-SMA, non-muscle myosin 
(NNM) and smooth muscle myosin heavy chain isoform 1 (SM-MHC or SM1). Moreover 
their phenotype and ultrastructure resemble proximal airway smooth muscle cells and 
fibroblasts. SM-MHC seems to be the marker for fully differentiated myofibroblasts as this 
protein expression is up-regulated later than α-SMA during myofibroblasts differentiation 
[67]. Unlike vimentin, desmin is expressed mostly in myofibroblasts at the alveolar ducts 
but not in those at the tip of the alveolar septum. Additionally, a family of actin-binding 
proteins, the drebrin is transiently expressed in myofibroblasts providing the mechanical 
elongation of secondary septa [127]. During lung alveolarization, myofibroblasts are the 
major cells found within the septal tips and are associated with elastin deposition [67].  
 
Function: 
 Myofibroblasts are responsible for tissue contractility or compliance determined by 
their stress fibers. Stress fibers are the structures in non-muscle cells which consist of actin 
filaments, crosslinking proteins, and myosin II motors. Myofibroblasts are the main source 
of ECM whose components (elastin and types of collagen) provide elastic properties to the 
lung parenchyma and maintain alveolar integrity for normal respiration and lung function. 
Elastin and collagen fibers form deposits in the thick walls of terminal air sacs and are 
elongated by the mechanical forces that give rise to primary and secondary septa [16, 48]. 
Thus myofibroblasts are the main cells driving alveolarization. Their number increases after 
birth and decreases after the microvascular maturation. In the adult lung, alveolar 
myofibroblasts are almost no detectable [48, 127]. However their number and proliferation 
capacity has been shown to increase during lung injury or fibrotic disease. During normal 
lung development and healing process, myofibroblasts progression and proliferation is 
terminated by apoptosis or their dedifferentiation [48].  
 Uncontrolled myofibroblasts proliferation and functions are the main cause of 
interstitial pulmonary fibrosis (IPF). In this state they produce excessive amount of 
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collagen and extracellular matrix deposition. Fibrotic lesions formed within thickened 
alveolar walls decreases the ability of gas exchange between the epithelium and the 
endothelium, and reduces lung compliance [67]. 
 
1.3.3. PDGFRα-positive cell 
 
Platelet-derived growth factor (PDGF) and its receptor (PDGFR): 
The PDGF molecule was first time isolated from human platelets. It is a covalent 
dimer of two different or same polypeptide chains A, B, C or D. The chains are linked to 
each other by disulfide bonds, encoded by distinct genes and inactive in their monomeric 
forms. There are four known homodimers and one heterodimer for PDGF molecules: 
PDGF-AA, -BB, -AB, -CC, and -DD [9]. Activated PDGFs more or less specifically bind 
to three different PDGF receptor forms: PDGFRαα (PDGFRα), PDGFRββ (PDGFRβ) or 
PDGFRαβ. The receptors also form active non-covalent dimers held together by the 
bivalent PDGF ligands. Heterodimeric PDGFRαβ delivers the highest range of signals than 
any of the other two homodimers. The extracellular ligand-binding sites of these receptors 
consist of five immunoglobulin-like domains (each of the chain). PDGFR-αα specifically 
interacts with PDGF-AA, PDGF-BB, PDGF-CC and PDGF-AB; PDGFR-ββ binds with 
high affinity to PDGF-DD and PDGF-BB; PDGFR-αβ is PDGF-AB and PDGF-BB specific 
(Figure 3). Some of the PDGF/ PDGFR interactions can be forced in vitro in cell culture. 
For example, PDGF-BB may activate PDGFRα, whereas this interaction seems to be not 
essential for PDGFRα-mediated signaling in vivo [9].  
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Figure 3 Members of tyrosine kinase receptor family (RTK), the PDGFRs and their activation 
patterns by different isoforms of PDGF. Extracellular IgG domains and cytosolic homodimeric or 
heterodimeric RTK domains are shown. Known in vitro and in vivo interactions are presented. 
Adopted from [7]. 
The PDGFRα (CD140a) is a ~122 kDa transmembrane tyrosine kinase receptor 
(RTK). It is enzymatically activated following ligand binding and auto-phosphorylation at 
multiple sites in the cytoplasmic domain of the molecule. In the dimeric receptor, the two 
subunits act as substrates for each other’s tyrosine kinase. Their phosphorylation increase 
the kinase activity and form docking sites for SH2 (Src Homology 2) domain-containing 
downstream signaling molecules. PDGFRα and PDGFRβ signaling activates several signal 
transduction pathways as the key downstream mediators, i.e.: Ras/mitogen-activated 
protein kinase (MAPK), phosphatidylinositol 3-phospahte kinase (PI3K), and 
phospholipase-γ (PLCγ). These signaling pathways contribute to the regulation of different 
cellular processes such as cell proliferation, differentiation, survival, cell motility and 
immunoresponse [9]. 
 PDGFRs and their ligands are organ and cell types specifically expressed. In the 
lung PDGF-A, PDGF-B, PDGF-C, PDGFRα, and PDGFRβ are expressed. Moreover, 
PDGF-B is expressed in vascular endothelial cells and appears to signal via PDGFRβ 
which is expressed in vascular smooth muscle cells (vSMC); PDGF-A and -C are expressed 
mostly in the epithelium and bind to the PDGFRα which is expressed by the interstitial 
fibroblasts. These two paracrine signaling loops do not interfere with each other. The 
PDGFs secretion and activation are compartmentalized in the extracellular space and its 
bioavailability is tightly regulated during development [9, 10, 49, 68].  
 
PDGFRα-positive cells morphology and phenotype: 
 During early lung development, namely the pseudoglandular stage, PDGF-A is 
expressed by the lung epithelium, whereas the PDGFRα-positive cells are mainly located in 
the mesenchyme surrounding the bronchial endbuds. During the canalicular and saccular 
stages, PDGFRα-positive cells spread along the surface of the future terminal sacculi 
(alveolar sacs) walls and differentiate into alveolar myofibroblasts. These cells 
differentiation is essential for alveolarization. Parabronchial smooth muscle cells (PBSM) 
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also express PDGFRα, however on much lower level. This suggests that alveolar 
myofibroblasts and smooth muscle cells may share the same cell lineage [14, 71]. 
 
Function of PDGFRα-positive cells: 
In 1985 Kaplan, et al. proposed that the lipofibroblasts are the precursors of the 
myofibroblasts [53]. However more likely, the precursor cells of myofibroblasts are 
considered as platelet-derived growth factor receptor α (PDGFRα)-positive mesenchymal 
cells [14]. PDGFRα is not only a marker of myofibroblast precursor, but activated by its 
ligand (simultaneously mitogen for smooth muscle cells, fibroblasts, and glia cells) has also 
functional consequences [71]. It promotes proliferation of PDGFRα-positive progenitor 
cells and regulates their differentiation, migration and survival [13, 14, 71]. PDGF-A/ 
PDGFRα signaling is required for postnatal alveolarization (septa elongation) but not for 
early lung development when the lung branching occurs [13].  
During late lung development the PDGF-A/ PDGFRα interactions are tightly related 
through epithelial-mesenchymal cross-talk. PDGF-A knockout in rodents causes a failure 
of alveolar septum formation. Homozygous PDGF-A-null mice are born with defects 
during alveolarization process, i.e. complete loss of myofibroblasts and septal elastin 
deposits [14, 71], while the PDGFRα-null mice die at the early embryonic stage or after 
birth from lung dysfunction [110]. Furthermore, overexpression of PDGF-A in the lung 
epithelium causes overgrowth of the lung mesenchyme, resulting in compression of the 
distal respiratory airways and lethality [68]. Until now no other genes have been shown to 
regulate alveolar myofibroblast differentiation. 
PDGFRα expression level positively correlates with the proliferation and 
differentiation capability of fibroblasts. It has been shown, that cells with higher PDGFRα 
expression (GFP expression in nuclei as marker of endogenous Pdgfrα gene) demonstrate 
increased αSMA protein expression level and proliferation during the septa formation in 
rodent [54]. Moreover, it has been shown that PDGF-A/ PDGFRα signaling inhibits 
lipofibroblast-promoting pathways [70] or the formation of adipose tissue [2]. On the other 
hand, neutral lipids co-localize with PDGFRα-GFPbright+ cells which reside in the proximity 
of alveolar type II cells but not in the PDGFRα-GFPdim+ cells of the bronchiolar wall of the 
adult mouse lung [5].  
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1.4. MicroRNA 
 
 MicroRNAs (miRNAs) are ~22nt long small endogenous non-coding RNAs that 
influence post-transcriptional gene regulation (RNAi – RNA interference). One miRNA 
can interact with a wide range of different target genes as well as many different miRNAs 
can synergistically influence one target gene [1, 6, 72]. The complexity and diversity of 
miRNAs play a key regulatory role in cell homeostasis and development, and their 
dysfunctions are implicated in many diseases [72]. 
 
1.4.1. Discovery 
 
 In 1993 the group of V. Ambros discovered a lin-4 gene in heterochronic mutants of 
Caenorhabditis elegans. It did not encode a protein but contained a small segment of 
homology to multiple motifs in the 3’-untranslated region (3’-UTR) of another 
heterochronic protein-coding gene lin-14 [66]. The discovery of another C.elegans miRNA 
gene let-7 with broad conservation among metazoans [91] helped to understand the 
importance of these small RNAs and initiated a rapid increase of studies on RNA 
interference biochemistry and miRNA biogenesis. Present miRNA studies involve both 
biological and bioinformatic methods. All known miRNAs are compiled in an official 
database miRBase (http://www.mirbase.org/) together with their hairpin transcripts, 
sequences and gene locations. The latest miRBase v20 contains 24521 hairpin precursor 
miRNAs expressing 30424 mature miRNA products in 206 species [59, 72]. Many other 
computational methods using specific algorithms were developed to identify putative 
miRNA targets (also including empirically validated targets) or biological processes in 
which miRNAs are involved [63, 72, 90, 107]. 
 MiRNA nomenclature: capitalized “miR”-X refers to the mature miRNAs; 
miRNAs with nearly identical sequences except for one or two nucleotides differ with 
small letter miR-Xa, miR-Xb, etc.; pre-miRNAs which lead to 100% identical mature 
miRNAs but that are located at different places in the genome: mir-X-1,-mir-X-2; the 
species of origin is designated with a three-letter prefix, e.g., hsa-miR-X (Homo sapiens), 
mmu-miR-X (Mus musculus), 'v' for viral and 'd' for Drosophila; when two mature 
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microRNAs originate from opposite arms of the same pre-miRNA, they are denoted with a 
-3p or -5p suffix; when the relative expression levels are known, an asterisk indicates 
miRNA expressed at low levels relative to the miRNA in the opposite arm of a hairpin, 
miR-X and miR-X* share a pre-miRNA hairpin. X refers to any miRNA number. 
 
1.4.2. Biogenesis 
 
 MiRNAs are endogenously expressed small RNAs that undergo extensive 
processing and are part of the RNA-induced silencing complex (RISC). In animals 
miRNAs are mostly transcribed as separate coding genes (60%; canonical biogenesis). 
About 15% of them are polycistronic genes coding multiple miRNAs. 25% of miRNAs are 
coded by short introns of protein-coding genes called mirtons (alternative biogenesis) [27, 
34, 122]. Polycistrons which contain more than two miRNA genes form miRNA clusters 
which members are not necessarily identical but may have similar expression patterns and 
target several categories of genes (physical relatedness). Homologous miRNAs that share 
similar sequence are collected in miRNA families [40]. The first step of miRNA biogenesis 
starts when the precise RNase III family enzymes liberate miRNA from its precursor 
transcripts (Figure 4). The primary miRNA (pri-miRNA) is transcribed by DNA-dependent 
RNA polymerase II (RNAPII) and similarly to protein-coding genes has 5’-end cap 
structure and 3’-end polyA tail [27, 34, 122]. The miRNA transcription is regulated by 
many transcription factors frequently in tissues-specific manner [61]. Pri-miRNA contains 
a region of imperfect dsRNA known as the stem–loop structure (hairpin) that is 
enzymatically removed later. The cleavage process begins when a double strand RNA 
binding domain (dsRBD) protein complex, the Pasha/DiGeorge syndrome critical region 
gene 8 (DGCR8) binds to the pri-miRNA simultaneously recruiting the Drosha enzyme 
(RNase III). This multiprotein complex is called the microprocessor. Drosha cleavage 
relieves a ~60–70nt precursor miRNA (pre-miRNA) with 2-nt single-stranded 3′ overhangs. 
The 3′ overhangs are recognized by the nuclear export protein Exportin 5 which actively 
transports pre-miRNA in a Ran–GTP-dependent manner to the cytoplasm. In the 
cytoplasm, pre-miRNA is cleaved by Dicer and forms a ~22nt miRNA:miRNA* duplex. 
Introduction 
13 
 
Dicer leaves its signature on the both ends of small miRNA duplexes, the 2-nt single-
stranded 3′ overhangs [27, 34, 122]. 
 Mirtrons do not undergo the conventional biogenesis. They overpass Drosha 
processing using the splicing machinery to generate pre-miRNAs. Excised, debranched and 
refolded they form short stem–loop structures that mimic pre-miRNAs and are processed 
into mature miRNAs by Dicer [27].  
 The mechanism of small RNA sorting that guides a particular small RNA strand to 
load into a specific Argonaute (AGO) family member is not entirely understood, however 
this is extremely crucial for the biological function of miRNAs. Argonaute proteins 
perform as a core of the RNA-induced silencing complex (RISC) and determine miRNAs 
biological function. Once a miRNA duplex is made, it seems that one strand is assessed and 
its fate determined. Only one miRNA-duplex strand is selectively stabilized during RISC 
assembly. Predominantly, it is the evolutionary preferred guide strand (miR strand) which 
binds complementary to its targets. The second strand – passenger strand (miR* strand) is 
discarded and degraded [27]. The strands arise from independent precursor molecules and 
different types of AGO proteins may compete for the selection of these strands from each 
duplex. This shows that miR* are not non-functional molecules, like thought before [27, 
128]. The proper strand choice depends on the enzymatic dicing of pre-miRNA that may 
influence the intrinsic structure, terminal nucleotides or thermodynamic properties of the 
miRNA duplex strands [27]. MiRNA sorting is also determined by structural interaction 
with AGO domains. The PAZ domain commonly hosts the 3’-OH termini of the miRNA, 
whereas the Mid domain forms a binding pocket that anchors a 5’-phosphate of the terminal 
nucleotide. The AGO C-terminal PIWI domain shows similarity to RNase H fold and 
harbors Asp–Asp–His residues responsible for catalytic activity (endonucleolytic cleavage 
of target gene transcripts) [27, 34]. In mammals, only AGO2 (mouse Eif2c2) forms an 
active endonuclease, although the catalytic triad is conserved in all four members of the 
AGO protein family (AGO1, AGO2, AGO3, AGO4) [21, 30, 34]. 
 The maturation of the miRNA/RISC complex is not well understood. One of the 
proposed mechanism is that miR* strands dissociate in a cleavage-independent manner by 
unwinding – a process that is facilitated by the presence of mismatches in the loaded 
duplexes [27, 51]. 
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Figure 4 Schematic summary of miRNA biogenesis. Boxes show enzymes or other proteins which 
are crucial for miRNA biogenesis and “maturation”. TRBP – TAR RNA binding protein, it recruits 
the Dicer complex to AGO2. * passenger miRNA strand. Modified according to [37, 122].  
 
1.4.3. Mechanism of action 
 
 MiRNAs regulate post-transcriptional gene expression. This regulation is 
accomplished by mature RNA-induced silencing complex (miRISC) formed by the guide 
miRNA strand and protein complex. The miRNA acts to guide the RISC complex to its 
target mRNA, while the AGO protein complex represses mRNA translation or induces 
deadenylation-dependent mRNA decay [27]. Most of the miRNAs bind to the 3’-UTRs 
(untranslated regions) of the target transcripts, less commonly to open reading frame (ORF) 
and 5’-UTRs. There are two patterns of binding (Figure 5). First, when the target site has 
perfect Watson–Crick complementarity to the 5’-end of the miRNA “seed region”. This 
nearly perfect complementarity is sufficient for miRNAs to suppress their targets or mRNA 
cleavage without requiring further base pairings at the 3’-end of the miRNAs [130]. 
MiRNA-directed target cleavage has only been reported in a few cases, and it is assumed to 
be the principal regulatory mode for endo-siRNAs and for piRNA-mediated repression 
[27]. The second type of binding has imperfect complementary base pairing at the 5’-end of 
the miRNAs and it is compensated via additional base pairings in the 3’-end of the 
miRNAs (3' compensatory binding). This type of binding causes translation repression 
[130].  
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 Activity of miRISC is optimized and regulated by many factors. These factors may 
bind to mRNA targets facilitating/stabilizing or counteracting miRISC activity. It is also 
known that an auto-regulatory feedback loop exists between the miRNAs and their target 
genes. This is greatly important during the cell fate determination and the development of 
organs. For instance, one miRNA can repress a mRNA that encodes factors involved in its 
own biogenesis or function, whereas the same mRNA may inhibit or activate this miRNA 
[61].  
 
Figure 5 The mechanism of action of miRNAs. Two different pathways of mRNA targets fate are 
shown (described above). mRNA processing takes place in processing bodies (P-bodies), the 
distinct foci within the cytoplasm of the cell consisting of many enzymes involved in mRNA 
turnover. Modified according to [37, 122]. 
 
1.4.4. MiRNAs in lung diseases and therapeutics 
 
MiRNAs are known to be key players involved in mammalian organs development 
and pathogenesis. It has been shown that in the lung miRNAs have a very specific 
expression profile highly conserved among the mammalian species. During lung 
development, miRNA networks are dynamically regulated [31]. The knowledge of the 
miRNA functions in physiological and pathological lung conditions is still poorly 
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understood. However, there is a known group of miRNAs involved in lung inflammation, 
viral infections, tumorigenesis and pulmonary diseases (Table 1) [112]. Many of these 
diseases are associated with lung structure remodeling due to uncontrolled mesenchymal or 
epithelial cells proliferation or apoptosis. In turn these cellular dysfunctions might be 
caused by many factors including up- or down-regulation of specific miRNAs or their 
target genes. In this case therapeutic approaches would require replacement of specific 
miRNA duplexes or reducing a miRNA’s level by using modified antisense 
oligonucleotides, so-called antimiRs or antagomirs [101]. Alternatively, gene therapy 
techniques could be used, i.e. DNA vectors that encodes a therapeutic protein 
(overexpression strategy) [82] or antisense siRNA/shRNA against dysfunctional mRNA 
(knockdown strategy) [121]. 
 
Table 1 MiRNAs involved in lung development, homeostasis and deregulated in 
pulmonary diseases [38, 83, 84, 105, 112, 117, 129].  
miRNA in the lung 
Homeostasis and lung development 
(fibroblasts regulation) 
miR-155, miR-26a, let-7, miR-29, miR-15/miR-
16, miR-223, miR-146a/b, -145, miR-17-92 
cluster 
inflammation and viral infections miR-146a/b, miR-21, -25, -27b, -100, -140, -142-
3p, -181c, -187, -194, -214, -223 and -224, miR-
200a, miR-155, miR-17-92 cluster, miR-574-5p 
Immune-mediated lung diseases miR-148a/b, miR-152, miR-21, miR-126, let-7, 
miR-29a, miR-155, miR-133a 
Cancer miR-155, let-7, miR-17-92 cluster, miR-21, miR-
210, miR-218, and miR-34 family 
Chronic obstructive pulmonary 
disease (COPD)/ emphysema 
let-7 family, miR-15b, -34a, -199a-5p, -125b, -
144, -145, -146a, -150, -1274a, -424, -107, -101, -
452, -449, -203, -222, -340, -223, -18a, -106a, -
99a, -365 
Idiopathic pulmonary fibrosis let-7d, miR-21, -145, -29, -154, -155, -338*, -127 
Cystic fibrosis miR-126, -101, -494, -138, -155 
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Pulmonary artery hypertension miR-17-92 cluster, miR-150, -21, -204, -27a, -17, 
-210, -206, -145, -143, -126 
Acute lung injury (ALI) and acute 
respiratory distress syndrome (ARDS) 
miR-21, -55, let-7, miR-146, -32*, -466d-5p, -
466f-3p, -127, -16 
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Chapter 2 
HYPOTHESIS  and AIMS 
 
 During late lung development, the stabilization and differentiation of the phenotype 
of fibroblasts subtypes are regulated in a time-dependent manner by specific molecular 
mechanisms. Dysfunctional fibroblast subtypes represent a central cause of structural lung 
diseases, i.e. pulmonary fibrosis, emphysema or COPD. PDGFRα-positive fibroblasts have 
been shown to be involved in the physiological process of alveolarization since they serve 
as precursor cells for myofibroblasts. Loss of the PDGFRα system leads to a complete 
failure of septum formation. While during lung development many key factors decide about 
the cell fate and hence whole organ, the same key factors might be involved in the lung 
disease onset. Therefore the understanding of the fibroblasts subsets function and 
differentiation biology is needed to develop new therapeutic regenerative strategies. Based 
on this background, the aim of the present study was to investigate mouse pulmonary 
PDGFRα-positive cells at different developmental time points and characterize these cells 
for: 
A) phenotype and differentiation capacity,  
B) miRNome and 
C) transcriptome 
in order to identify new possible target molecules. 
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Chapter 3 
METHODICAL BASIS for miRNome and 
TRANSCRIPTOM ANALYSIS 
 
Molecular biology techniques were used to screen the whole miRNome (miRNA 
profile) and transcriptome (gene expression level) of PDGFRα-positive cells. TaqMan Low 
Density Array (TLDA) was used to analyze the miRNome, whereas Next-Generation 
Sequencing (NGS) was used to analyze the transcriptome.  
 
3.1. TaqMan Low Density Array 
 
The following method is based on TaqMan qPCR (Figure 7) and it requires the use 
of specific primers that can transcribe small miRNAs into cDNA. These small RNA-
specific stem-loop primers are specific for the 3’polyadenylated ends of miRNA (Figure 6).  
 
Figure 6 Reverse transcription (RT) of miRNA. Small RNA-specific stem-loop RT primers are 
specific for the 3’polyadenylated end of microRNA. Adopted from handbook part no. 4425446 Rev. 
A, 1/2009 (Applied Biosystems). 
TaqMan miRNA Arrays are specific for all mature miRNAs and can distinguish between 
miRNAs that differ by only one nucleotide. 
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Figure 7 Steps in TaqMan real-time PCR. Each TaqMan minor groove binder (MGB) probe 
contains: a reporter dye (FAM™ dye) linked to the 5’-end of the probe, MGB at the 3’-end of the 
probe [nonfluorescent quencher (NFQ)]. The short probes have great specificity to the target cDNA 
and increase the sensitivity of qPCR. The 5’ to 3’ nuclease activity of the DNA polymerase system 
allows amplifying cDNA. Adopted from handbook part no. 4425446 Rev. A, 1/2009 (Applied 
Biosystems). 
 
3.2. Next-Generation Sequencing 
 
In 1977 Fred Sanger and Alan R. Coulson published two methodological papers on 
rapid determination of DNA sequence [dideoxynucleotide (ddNTP) chain termination 
sequencing]. Sanger sequencing relies on enzymatic synthesis of DNA in the presence of 
chain-terminating inhibitors of DNA polymerase, i.e. ddATP, ddCTP, ddGTP and ddTTP. 
These four modified nucleotides are characterized by the absence of a hydroxyl group and 
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inhibit DNA strand elongation. In Sanger sequencing analysis, DNA synthesis reaction is 
carried out four times in parallel i.e. with only one type of dideoxynucleotide and DNA 
products are identified by radioactivity [radioactive deoxynucleotide (dNTP) 32P- or 35S-
dATP] on polyacrylamide gel [99]. However, use of advanced fluorescent dye-labelled 
ddNTPs permits sequencing in a single reaction with all four ddNTPs (use of capillary gel 
electrophoresis and CCD camera with signals translated into a chromatogram) [109]. 
Sanger sequencing method marked the beginning of a new era for deciphering complete 
genes and later entire genomes [99]. In the last few years this sequencing technique has 
been replaced by Next-Generation Sequencing (high-throughput sequencing) methods, 
especially for large-scale automated genome or transcriptome analyses. DNA cloning 
necessity was eliminated by DNA immobilization and repeated amplification. High-
throughput sequencing technologies are intended to lower the cost of DNA sequencing by 
generating a massive number of short sequence reads (short sequence of nucleotides) in a 
single experiment (thousands or millions of sequences concurrently) [41, 52]. The next 
generation sequence reads are produced from fragmented DNA libraries which later must 
be assembled together. For RNA sequencing, the libraries are produced from fragmented 
RNA molecules that are transcribed into cDNA. Relatively little input DNA/ RNA is 
needed to produce a library. The DNA or RNA are fragmented, tagged by specific adaptor 
oligos and amplified. The majority of next-generation sequencers produce shorter read 
lengths (35–250 bp) than capillary sequencers (650–800 bp); what also can impact the 
utility of data for various applications such as de novo assembly. As no sequencing 
technology is perfect and each instrument will generate different types and amounts of 
errors,  it is necessary to understand, identify and exclude error-types that may impact the 
interpretation of downstream analysis [76]. 
Different next-generation sequencing methods are commercially available:  
a) Single-molecule real-time sequencing (Pacific Bio) 
b) Sequencing by synthesis  
i. Ion Torrent  – detection by ion release 
ii. Illumina – detection by fluorescent dyes 
iii. Pyrosequencing (454) 
c) Sequencing by ligation (SOLiD sequencing) 
Methodical Basis for miRNome and Transcriptome Analysis 
22 
 
 In the current work we aim to sequence the RNA isolated from pulmonary 
PDGFR-positive cells using Ion Torrent sequencer. 
RNA-Seq (sequencing), so-called Whole Transcriptome Shotgun Sequencing 
(WTSS) uses the capabilities of next-generation sequencing to reveal a snapshot of RNA 
presence (gene presence or alternatively spliced transcript of a gene) and quantity 
(expression level of genes) at any particular time in a specific cell type, tissue or organ. The 
number of mRNA molecules encoding an individual gene provides information about 
specific cell phenotype (when counting protein-coding genes) [23].  
 
3.2.1. Ion Torrent semiconductor sequencing 
 
It is a system based on standard sequencing chemistry (A, C, G, T) directly 
translated into digital information (0, 1) on a semiconductor chip. The method is based on 
detection of hydrogen ions (H
+
) released during the DNA polymerization. A micro-well 
containing a single-stranded template DNA (library) is flooded with a single type of 
nucleotide. If the introduced nucleotide is complementary to the leading template 
nucleotide, it is incorporated into the growing complementary strand. This causes the 
release of a hydrogen ion that triggers a hypersensitive ion sensor (by changing pH), which 
indicates that a reaction had occurred. Homopolymer repeats i.e. multiple nucleotides of the 
same type are incorporated in a single cycle. This leads to the release of the corresponding 
number of hydrogens and a proportionally higher electronic signal [97]. 
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Figure 8 Steps of the Ion Torrent sequencing process (a). DNA library fragmentation and ligation 
to forward/reverse adapters (before this step RNA must be reverse transcribed into cDNA) (b). 
Clonal amplification of the DNA fragments occurs on the template-carrying beads during emulsion 
PCR (c). Polymerization of nucleotides releases H
+
 ions causing a pH change. The detection occurs 
at the thin layer (semiconductor) located at the bottom of each micro-well. If homopolymer repeats 
(e.g. AAA) are present, the electronic signal is higher. All four nucleotides are cyclically flowed in 
an automated run (d). According to [96]. 
 
3.2.1.1. Preparation of cDNA libraries 
 
           Total RNA used for transcriptome sequencing needs to be purified from the 
cytoplasmic and mitochondrial ribosomal RNA (rRNA) which constitutes the majority 
(>90%) of the total RNA. It can be achieved by RNA hybridization to bait oligos bound to 
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beads. Alternatively, poly(A) selection of mRNA can be used for this purpose. rRNA 
removal increases the capacity to retrieve data from the remaining portion of the 
transcriptome (mRNA), and small non-coding RNAs. The RNA has to be fragmented by 
RNase III treatment and then reverse transcribed into complementary DNA (cDNA). The 
purpose of preparing a library is to link the DNA fragment at its both ends to 
forward/reverse adapters with bar codes (barcoded primers). Similar distribution between 
the samples is desired; therefore median size of the library fragments is selected (100, 200, 
300 or 400 bases). For sequencing of RNA other than mRNA, the library preparation is 
modified. For small RNA targets, such as miRNA, RNA is isolated through size selection. 
The library molar concentration and average size of the fragments are monitored using a 
bioanalyzer chip. This information determines the dilution factor which is necessary to set 
the ideal ratio of DNA fragment library/ Ion Sphere Particle (ISPs) for the next stage of 
emulsion PCR [12, 25]. 
 
3.2.1.2. Preparation of the sequencing template 
 
Preparation of the sequencing template is an automated step that allows the clonal 
amplification on the surface of ion sphere particles (beads) to which a fragment library is 
amplified. The clonal amplification is performed during the emulsion PCR (ePCR) (Figure 
9) and helps to achieve a detection threshold signal necessary during the process of 
sequencing. Three parts enable the automated delivery of the templated ion sphere particles. 
First, a specific microenvironment is necessary to create millions of microreactors in which 
clonal amplification occurs. Secondly, a fully integrated thermal cycler and a disposable 
path amplification plate system are needed. Thirdly, an integrated centrifuge recovers the 
templated ion sphere particles. The biotinylated PCR primers allow the enrichment of the 
templated ion sphere particles from the reaction mix by binding to streptavidin-linked 
magnetic beads. Monoclonality of the amplified cDNA is desired because it alone is the 
source of the sequencing data, i.e. only ISPs with a single fragment from the library could 
be analyzed [12, 25]. 
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Figure 9 Emulsion PCR steps. According to Andy Vierstraete. Department of Biology, Faculty of 
Science, Ghent University. 2012. 
 
3.2.1.3. Sequencing 
 
Prior to sequencing, all reagents are booted to a pH ~ 7.8. The sequencing template, 
the primers and the polymerase are loaded onto the chip. For example, Ion PI™ Chip v2 
may provide: 10 giga base pairs (Gb) of sequence data in 60-80 million reads. The adapters 
contain sequences that allow the primers to bind and initiate the sequencing reads. Each 
polymerization of unmodified nucleotides releases H
+
 ions causing a pH change. Detection 
occurs at the thin layer (semiconductor) located at the bottom of each micro-well [12, 25]. 
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3.2.1.4. Data quality and depth of coverage 
 
All raw data is generated as ionograms and transferred to the Torrent Server. The 
algorithm “base calling” allows data (reads) conversion into FASTQ format i.e. text-based 
format of nucleotide sequence letters A, G, C, T and quality score. In FASTQ format each 
nucleotide is associated to an ASCII (American Standard Code for Information 
Interchange)-encoded quality number corresponding to a Phred score (Q) which is directly 
translated into the probability (p-value) of incorrect base call [24, 28]. These quality scores 
are generated by a Phred-like algorithm (FastQC software and other trimming tools) to 
determine highly accurate consensus sequences and to estimate their quality (the 
probability that a base is called correctly). The scores are listed as Q values where Q20 
score is considered as an acceptably accurate base call (>99% accuracy; Q30>99.9%, etc.). 
Data trimming serves a dual purpose. First, it monitors parts of the reads with poor quality 
and secondly, it removes potential adapters’ contamination. Trimming of the sequencing 
data gives a better result in the further analysis. Automated DNA sequencers occasionally 
produce poor quality reads, particularly near the sequencing primer site and towards the end 
of longer sequence runs [12]. Additional filters are used to remove wildly varying lengths 
or polyclonal reads i.e. missequenced when two different templates are amplified on a 
single bead, resulting in a hybrid sequence [12, 100]. Depth of coverage stands for the 
average number of times a given region (sequence of nucleotides) has been sequenced by 
independent reads. Deep sequencing indicates that the depth of the process is many times 
larger than the length of the sequence under study (low expression of a gene can be 
detected). Correlation of gene abundance between the samples or replicates can be 
measured as a Fragments Per Kilobase of the transcript per Million mapped reads (FPKM) 
plotted on a log10 transformed scale. High degree of correlation between the pairs indicates 
that similar transcript (gene) quantities are consistently detected in the samples 
(reproducibility of the method).  
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3.2.1.5. Transcriptome assembly/ mapping 
 
Two different methods are used to produce a transcriptome from the raw sequence 
reads, i.e. 1. de novo assembly and 2. mapping to a reference genome. The first approach 
does not rely on the presence of the reference genome in order to reconstruct the nucleotide 
sequence. Due to the small size of the short reads, de novo assembly may be difficult. The 
second approach relies on the reference genome to map millions of reads. Recently 
specialized algorithms for transcriptome alignment have been developed, e.g. Bowtie for 
RNA-Seq short read alignment [65], TopHat for aligning reads to a reference genome to 
discover splice sites [115], Cufflinks to assemble the transcripts and compare/ merge them 
with others [116]. These tools can also be combined together to form a comprehensive 
system.  
  
3.2.1.6. Sequencing data analysis 
 
RNA-Seq data allows the characterization of a gene expression in cells or tissue via 
measurement of mRNA levels. For instance it can be determined how cells differ between a 
healthy or diseased state or at different developmental time points. Cuffdiff2 algorithm may 
be employed to estimate the abundance of transcripts (genes) and their differential 
expression in the samples. Gene expression levels are frequently normalized by the total 
number of mapped reads and expressed as Fragments Per Kilobase of the transcript per 
Million mapped reads (FPKM). Cuffdiff2 assumes that the expression of a transcript in 
each condition can be measured by counting the number of generated fragments. Thus, a 
change in the expression level of a transcript is measured by comparing its fragment count 
in each condition. The resulting p-values are corrected with Benjamini-Hochberg for 
multiple testing to get a meaningful FDR (False discovery rate, also called q-value). This 
value describes the probability that the observed expression difference represents a change 
when compared to the null hypothesis of no change. It is based on a statistical model 
evaluating measurement error, technical variability and cross-replicate biological variability 
[116]. 
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Chapter 4 
MATERIALS and METHODS 
 
4.1. Animals 
 
Lungs were harvested from wild type (WT) or transgenic mice. Mice were 
sacrificed by isoflurane overdose (cat. no.: 1001936060; Baxter, Deerfield, USA). All 
mouse lines were housed according to European Laboratory Animal Welfare Act and 
Regulations in animal housing facility in Max-Planck-Institute for Heart and Lung in Bad 
Nauheim. Mice were housed in a barrier facility with purified air and water, supplied with 
food and water ad libitum, and exposed to a 12:12-h light-dark cycle. All transgenic 
animals were maintained in C57BL/6 background. WT mice were purchased from Charles 
River. The file reference number from the ethics committee along with the permission for 
animal laboratory use, is as follow: B2/320 at the Regierungspräsidium Darmstadt. 
Transgenic mouse lines: 
a) B6.129S4-Pdgfratm11(EGFP)Sor/J; stock number: 007669; (PDGFRa-eGFP). Pdgfrα 
promoter drives constitutive expression of the H2B-eGFP fusion gene. Green 
fluorescence is detected in cell nucleus. The mouse line was donated by P. Soriano, 
Mount Sinai School of Medicine, USA. The mice were maintained as heterozygote. The 
line has been reported previously [42]. 
b) B6.FVB-Tg(Myh11-cre/ERT2)1Soff/J; stock number: 019079; (SmMHC/CreER). A 
CreERT2 sequence, a polyadenylation signal, and a frt-flanked beta-lactamase cassette 
were inserted into the initiation codon of Myh11 (smooth muscle myosin, heavy 
polypeptide 11). The transgene is integrated on the Y chromosome. The Line was 
donated by Prof. Dr. S. Offermanns, Max-Planck-Institute for Heart and Lung, 
Germany. It has been described previously [124]. To activate CreERT2 recombinase, a 
dose of 0.5mg tamoxifen per neonate was injected intraperitoneally at 3 subsequent 
days before harvesting the lung. Tamoxifen stock solution of 20mg/ml: tamoxifen 
powder (cat. no.: T5648, Sigma-Aldrich, St. Louis, USA) dissolved in normal corn oil 
Materials and Methods 
29 
 
by shaking for about 1h at room temperature. Tamoxifen was stored at -20°C protected 
from light. 
c) STOCK Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J; stock number: 007576; 
mTom/mGFP (mT/mG). The mice possess loxP sites on either side of a membrane-
targeted tdTomato (mT) cassette and express a strong red fluorescence in all tissues and 
cell types. The line was bred to a mouse line expressing Cre recombinase. The offspring 
had the mT cassette deleted in the cre expressing tissue(s) after tamoxifen treatment.  
mT cassette deletion activated the expression of membrane-targeted EGFP (mG) 
cassette located downstream (Figure 10). Mice were purchased from the Jackson 
Laboratory and maintained as homozygote. The line has been reported previously [86].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Schematic diagram of double transgenic SmMHC/CreERT2 and mT/mG  mouse. Cre-
mediated recombination (tamoxifen inducible) causes mT deletion. As a result SmMHC-positive 
cells are characterized by membrane green fluorescence (mG; mGFP, *). * = active fluorescence. 
d) B6.Cg-Tg(Myh11-cre,-EGFP)2Mik/J; stock number: 007742; smMHC/Cre/eGFP. 
Smooth muscle myosin heavy chain (smMHC or Myh11) promoter directs bicistronic 
Cre and EGFP (enhanced green fluorescent) protein expression. Hemizygotes from 
founder line SMCG2 (SM2Cre/GFP) display intense EGFP fluorescence restricted to 
vascular and nonvascular smooth muscle with strong concordance between cre 
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expression and EGFP fluorescence. The mouse line was obtained from the Jackson 
Laboratory and maintained as heterozygote. The line has been reported previously 
[126]. 
 
4.2. Genotyping 
 
DNA isolation from tail cuts 
DNA was isolated from mouse tails obtained 1-2 weeks after birth. Tails were 
placed in 1.5ml tubes (cat. no.: 72.706; Sarstedt, Nümbrecht, Germany) and digested in 
500µl lysis buffer (pH=8, 50mM Tris/HCL; 100mM EDTA; 100mM NaCl; 1% SDS) + 5µl 
proteinase K (stock solution 20mg/ml) (cat. no.: 7528.1; Roth, Karlsruhe, Germany). 
Samples were incubated at 55°C shaking overnight. They were centrifuged next day for 
10min, at 13000rpm, 4°C (Eppendorf Centrifuge 5430R, Hamburg, Germany). 
Supernatants were collected into new 1.5ml tubes. 500µl of isopropanol (cat. no.: 6752.2; 
Roth, Karlsruhe, Germany) was added to supernatants and centrifuged for 10min at 
13000rpm, 4°C. DNA pellets were washed with 500µl of 70% ethanol (cat. no.: 603-002-
00-5; Merck, Darmstadt, Germany) and centrifuged for 10min at 13000rpm, 4°C. DNA 
pellets were dried and 100µl of T 1/10 E buffer (pH=8, 50mM Tris/HCl; 100mM EDTA) 
was added. Samples were incubated at 55°C in a shaking thermoblock overnight or 2h.  
PCR and electrophoresis 
2µl of DNA from each sample was used for semi-quantitative PCR followed by 
agarose gel electrophoresis. PCR mixture was prepared with 5µl of ImmoMix™ (cat. no.: 
BIO-25020; Bioline, Luckenwalde, Germany) master mix, 0.25µl appropriate primers 
(purchased from Eurofins) and supplemented by ddH2O up to 10µl. Reaction mix was 
prepared in 0.2ml polypropylene 8-tube strips (cat. no.: 673271, 683271; GBO, 
Frickenhausen, Germany).  
Following primers were used for genotyping of the specific mouse lines:  
a) PDGFRa-eGFP (product size: mutant = 242bp, wild type = 451bp):  
5’ - CCC TTG TGG TCA TGC CAA AC - 3’ wild type forward 
5’ - GCT TTT GCC TCC ATT ACA CTG G - 3’ wild type reverse 
5’ - ACG AAG TTA TTA GGT CCC TCG AC - 3’ mutant reverse 
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b) SmMHC/CreER (product size: transgene = 287bp, internal positive control = 324bp): 
5’ - TGACCCCATCTCTTCACTCC - 3’ SMWT1        
5’ - AACTCCACGACCACCTCATC - 3’ SMWT2        
5’ - AGTCCCTCACATCCTCAGGTT - 3’ phCREAS1    
c) mTom/mGFP (product size: mutant = 250bp, wild type = 330bp): 
5’ - CTC TGC TGC CTC CTG GCT TCT - 3’ wild type forward 
5’ - CGA GGC GGA TCA CAA GCA ATA - 3’ wild type reverse 
5’ - TCA ATG GGC GGG GGT CGT T - 3’ mutant reverse 
d) smMHC/Cre/eGFP (transgene = ~100bp, internal positive control = 324bp): 
5’ - GCG GTC TGG CAG TAA AAA CTA TC - 3’ transgene 
5’ - GTG AAA CAG CAT TGC TGT CAC TT - 3’ transgene 
5’ - CTA GGC CAC AGA ATT GAA AGA TCT - 3’ internal positive control forward 
5’ - GTA GGT GGA AAT TCT AGC ATC ATC C- 3’ internal positive control reverse 
 
 The PCR products were run on agarose gel (cat. no.: 2267.4; Roth, Karlsruhe, 
Germany) containing of 4µl ethidium bromide (10mg/ml; cat. no.: 2218.2; Roth, Karlsruhe, 
Germany) in 1xTAE buffer (40mM Tris acetate and 1mM EDTA) at 120V for 50-60min. 
The DNA products size separation was visualized under UV lamp. As a size marker 100bp 
ladder (cat. no.: M-214; Jena Bioscience, Jena, Germany) was used.  
 
4.3. Primary cells isolation 
 
Mouse primary cells were isolated from PBS-perfused and shredded lungs. 
Following lysis mixture was used: serum-free Dulbecco’s modified Eagle’s medium 
(DMEM) + GlutaMax (cat. no.: 31966-021; Life Technologies, Carlsbad, USA) containing 
0.2% collagenase B (0.243U/mg; cat. no.: 11088815001; Roche, Penzberg, Germany), 10 
U/cm
2
 dispase (5000 caseinolytic units, cat. no.: 354235; BD, Franklin Lakes, USA) and 
0.5µg/µl DNase (4065.6U/mg; cat. no.: 18535; Serva, Heidelberg, Germany). Lungs 
shredded on petri dishes were shaken for 30-40min at 37°C, 5% CO2. Enzymatic activity of 
lysis reaction was stopped by adding DMEM/F12 medium (cat. no.: 21331-020; Life 
Technologies, Carlsbad, USA) containing 10% fetal calf serum (FCS; cat. no.: A15-101) 
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and 1% penicillin/streptomycin (cat. no.: P11-010) both purchased from PAA, Pasching, 
Austria. Undigested remains were eliminated by filtering the cell suspension through a cell 
strainer with a 100-µm nylon mesh (cat. no.: 352360; BD, Franklin Lakes, USA). The 
singe-cells suspension was centrifuged (Heraeus Multifuge 1S; Thermo Scientific, 
Rockford, USA) at 2000rpm, 10min, RT in a 50-ml polypropylene centrifuge tube (cat. no.: 
227261; GBO, Frickenhausen, Germany). Red blood cells were lysed in lysis buffer 
[pH=7.4; 0.15M NH4Cl (cat. no.: K298.1), 10mM KHCO3 (cat. no.: P748.1), 0.1mM 
EDTA (cat. no.: 8040.3); all purchased from Roth, Karlsruhe, Germany], for 5min in RT. 
Pelleted (1500rpm, 5min, RT) cells were washed successively with Dulbecco’s PBS (cat. 
no.: H15-002; PAA, Paschin, Austia), and centrifuged at 1500rpm, 5min. Cell pellets were 
frozen at -80°C or directly used for further experiments. Cell number was established 
microscopically (Zeiss Primo Vert; Oberkochen, Germany) using a Neubauer 
haemocytometer chamber (cat. no.: 0640010; Marienfeld, Lauda-Königshofen, Germany).  
 
4.4. Fluorescent-activated cell sorting (FACS) 
 
Cells sorting was performed using FACSAria™ III cell sorter with BD 
FACSDiva™ software v6.1.3 (BD Bioscience, San Jose, USA). Cell suspension was kept 
in 2.5ml sorting buffer [0.1% BSA (cat. no.: K45-001; PAA, Pasching, Austria), 2mM 
EDTA (cat. no.: 8040.3; Roth, Karlsruhe, Germany]. Samples in polystyrene tubes (cat. 
no.: 352052; BD Falcon, San Jose, USA) were transported on ice within 30min to the 
Institute for Clinical Immunology and Transfusion Medicine facility in Giessen. 100-μm 
nozzle and argon-ion laser (488-nm) were used to sort the cells. Cells were sorted into 
DMEM medium (cat. no.: 31966-021; Gibco, Grand Island, USA) within ca. 2h. Post-
sorting test was run using sytox blue. The cells viability and purity was measured. Sorted 
cells were pelleted and total RNA was isolated. 
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4.5. Lung primary cells culture 
 
Lung primary cells were cultured in DMEM/F12 medium (cat. no.: 21331-020; 
Gibco, Grand Island, USA) supplemented with 10% FCS (cat. no.: A15-101) and 1% 
penicilin/streptomycin cat. no.: P11-010) both purchase from PAA, Pasching, Austria. Cells 
were seeded on 100mm (3.5 × 10
6 
cells), 60mm (1 × 10
6 
cells) polystyrene culture dishes 
(cat. no.: 664160 and 628160; GBO, Frickenhausen, Germany) or chamber slides (1.3 × 10
5 
cells) (cat. no.: 354108; BD Bioscience, San Jose, USA). Cells were incubated at 37°C, 5% 
CO2 conditions for 2, 24, 48 or 72h.  
 
4.6. Positive and negative cell selection using magnetic Dynabeads 
 
Dynabeads sheep anti-rat IgG (cat. no.: 110.35; Invitrogen, Carlsbad, USA) were 
used according to the manufacturer’s instruction. Rat anti-PDGFRα (cat. no.: ab90967; 
Abcam, Cambridge, USA) and rat anti-CD45 (cat. no.: 550539; BD Bioscience, San Jose, 
USA) antibodies were used to separate PDGFRα-positive cells or leucocytes, respectively. 
Leucocytes were removed from samples using negative selection. Beads-unbounded cells 
were transferred to new tubes containing beads/anti-PDGFRα antibody complexes in 
sorting buffer (PBS with 0.1% BSA, 2mM EDTA). Cells were incubated in 5-ml 
polystyrene tubes (cat. no.: 115 101; GBO, Frickenhausen, Germany) on ice by gently 
mixing time to time. After 30min of incubation cells were washed 3 times with sorting 
buffer. Separated cells were centrifuged for 5min at 10000rpm, 4°C. Cell pellets were 
directly frozen in RNA later at -80°C (cat. no.: AM7020; Ambion, Carlsbad, USA). 
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Figure 11 Principle of magnetic Dynabeads cell sorting. Bead-sorted cells were used for total 
RNA purification. In comparison FACSorting method was shown. MPC= Magnetic Particle 
Concentrator. 
 
4.7. Immunofluorescence, confocal and fluorescence microscopy 
imaging 
 
4.7.1. Tissue preparation 
 
PBS-perfused lungs were inflated intratrachealy with 1:1 PBS (cat no.: H15-002; 
PAA, Paschin, Austia) and Tissue-Tek (cat. no.: 4583; Sakura, Torrance, USA). Removed 
lungs were embedded in Tissue-Tek and immediately frozen in 2-methylbutane (cat. no.: 
3927.1; Roth, Karlsruhe, Germany) kept on dry ice. Lungs from smMHC/CreER-mT/mG 
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and smMHC/Cre/EGFP transgenic mice were inflated intratrachealy with 4% PFA and 
incubated overnight in 4% PFA at 4°C. Next day, the lungs were washed with PBS for 2h 
at 4°C, embedded in Tissue-Tek and frozen in 2-methylbutane on dry ice. 10µm lung 
cryosections were cut using Leica CM3050S cryostat/microtome and adhered on polysine 
adhesion slides (cat. no.: 10143265; Thermo Scientific, Waltham, USA). Tissue slides were 
kept at -20°C.   
 
4.7.2. Immunohistochemistry and immunocytology 
 
10µm lung tissue slides were fixed with 1:1 mixture of methanol (cat. no.: 4627.5) 
and aceton (cat. no.: 9372.2) (both from Roth, Karlsruhe, Germany) within 10min at RT. 
Slides were washed 2-3 times with PBS (137mM NaCl, 2mM KH2PO4, 10mM Na2HPO4 ∙ 
2H2O, pH=7.4). Nonspecific binding of antibodies was blocked with 1:1 histobuffer (3% 
BSA in 1x PBS with 0.2% Triton X-100 cat. no.: 3051.3; Roth, Karlsruhe, Germany) and 
goat serum (cat. no.: 16210-072; Life Technologies, Carlsbad, USA) within 1h at RT. All 
antibodies were diluted in histobuffer and incubated in black box filled with water at RT. 
Primary antibodies were added directly after blocking and incubated on the slides for 1h. 
Secondary antibodies were added and incubated for 45-60min. If the staining was double or 
triple the steps were repeated. Nuclei were stained for 20min at RT with DAPI (1:1000; cat. 
no.: D1306), To-Pro3 (1:2000; cat. no.: T3605) or Sytox blue (1:1000; cat. no.: S11348), all 
three obtained from Life Technologies, Carlsbad, USA. After each staining, slides were 
washed extensively with PBS. After last staining, tissue slides were incubated in 4% PFA 
(cat. no.: 441244; Sigma-Aldrich, St. Louis, USA) for 5min and washed with PBS. The 
same steps were applied for cells staining in chamber slides; all incubation times were 
shortened by half. Slides were mounted with mowiol (cat. no.: 475904; Merck, Darmstadt, 
Germany).  
1:300 rabbit anti- ADRP polyclonal antibody (cat. no.: ab52356) and 1:300 rat anti- 
PDGFR alpha monoclonal antibody (cat. no.: ab 90967) from abcam (Cambridge, USA) 
were used. 1:500 mouse IgG2a (cat. no.: M5409), 1:500 mouse anti- actin α-smooth 
muscle-Cy3 (cat. no.: C6198) and 1:500 mouse anti- vimentin (cat. no.: V 6630) 
monoclonal antibodies purchased from Sigma-Aldrich, St. Louis, USA were used. 1:300 rat 
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IgG2a (cat. no.: 553927), 1:500 rat anti- CD45 (cat. no.: 550539) 1:500 and rat anti- CD31 
(cat. no.: 550274) monoclonal antibodies from BD Biosciences, Franklin Lakes, USA were 
used. 1:500 Rabbit anti- cytokeratin polyclonal antibody (cat. no.: Z0622; Dako, Glostrup, 
Denmark), 1:500 rabbit anti- collagen I polyclonal antibody (cat. no.: T 40777R; Rockland, 
Gilbertsville, USA), 1:500 goat anti- GFP-FITC antibody (cat. no.: NB100-1771; Novus 
Biologicals, Littleton, USA), 1:300 rabbit IgG polyclonal antibody (cat. no.: 2729, Cell 
Signaling Technology, Danvers, USA), 1:700 mouse IgG2b-Cy3 (cat. no.: 0104-12; 
Southern Biotech, Birmingham, USA) were also used. Alexa Fluor (AF) 488 (cat. no.: 
A11008) or AF 555 (cat. no.: A21428) goat anti- rabbit IgG, AF 488 (cat. no.: A11006) or 
AF 555 (cat. no.: A21434) goat anti- rat IgG, AF 488 (cat. no.: A11001) goat anti- mouse 
IgG secondary antibodies were used and purchased from Invitrogen, Carlsbad, USA, all of 
them in 1:1000 dilution.  
Zeiss LSM 710 confocal microscope (Carl Zeiss, Oberkochen, Germany) with ZEN 
2011 Microscope Software or Leica DFC360 FX Fluorescent microscope (Leica 
Microsystem; Wetzlar, Germany) with Leica Application Suite (LAS) AF microscope 
software were used. 
 
4.8. Total RNA isolation, real-time PCR 
 
Total RNA was purified with GeneJET™ RNA Purification kit (cat. no.: K0731; 
Fermentas Thermo Fisher Scientific, St. Leon-Rot, Germany) according to the 
manufacturer’s instructions. 100ng of total RNA was used for cDNA synthesis. cDNA was 
synthesized using High Capacity cDNA Reverse Transcription Kit (cat. no.: 4368814; 
Applied Biosystems, Foster City, USA) according to the manufacturer’s instructions. 0.2-
ml polypropylene 8-tube strips (cat. no.: 673271, 683271; GBO, Frickenhausen, Germany) 
were used. Eppendorf Mastercycler ep Gradient S thermal cycler (Eppendorf, Hamburg, 
Germany) was used. 
cDNA synthesis protocol (reaction volume 20µl): 
1: 25.0°C for 10min 
2: 37.0°C for 120min 
3: 85.0°C for 5min 
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4: 4.0°C hold 
Real-time PCR was performed using a SensiMix SYBR No-ROX kit (cat. no.: 
QT650-05; Bioline, Luckenwalde, Germany) according to the manufacturer’s instructions. 
2µl of cDNA was used. The primers used to amplify mouse Pdgfrα transcript were: 
forward 5′ GGAGCCTGAGCTTTGAGCGACG 3′ and reverse 5′ 
GAAAGACCTGGTGGGAGG TCCC 3′. The primers for mouse Adrp were: forward 5′ 
CGACGACACC GATGAGTCCCAC 3′ and reverse 5′ TCAGGTTGCGGGCGATAGCC 
3′. The primers for mouse Myh11 (Smmhc) were: forward 5′ 
CAGCGCATCAACGCCAACCG 3′ and reverse 5′ AGCCTCGTTTCCTCTCCTGGTGG 
3′. Mouse porphobilinogen deaminase (Pbgd) transcript was used as an internal control. 
The primers for Pbgd were: forward 5′ ATGTCCGGTAACGGCGGC 3′ and reverse 5′ 
GGTACAAGGCTTTCAGCATCGC 3′. All the primer pairs were separated by at least one 
intron to exclude genomic DNA contamination and checked for primer efficiency. Bio-Rad 
C1000 thermal cycler with CFX96 system (Hercules, USA) was used. 
Real-time PCR protocol (reaction volume 15µl): 
1: 95.0°C for 6:00 min 
2: 95.0°C for 0:10 sec 
3: 59.0°C for 0:10 sec 
4: 72.0°C for 0:15 sec 
Plate Read 
5: GOTO 2; 44 more times 
6: 95.0°C for 0:10 sec 
7: Melt Curve 65°C to 95°C: Increment 0.5°C for 0:03 sec 
Plate Read 
 
4.9. Protein isolation, western blot 
 
Cells were lysed in 1x RIPA lysis buffer (cat. no.: 89901) supplemented with 1:100 
protease and phosphotase inhibitor cocktail (cat. no.: 1861284), and 1:100 EDTA solution 
(cat. no.: 1861283; all purchase from Thermo Scientific, Rockford, USA). Samples were 
centrifuged (Eppendorf Centrifuge 5430R, Hamburg, Germany) for 30min at 13000rpm, 
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4°C. Supernatants were collected into new 2-ml tubes. Proteins concentration was 
measured using a Dc protein assay kit (cat. no.: 500-0113; Bio-Rad, Hercules, CA, USA) 
according to the manufacturer’s instructions and read using Nano Quant Infinite M200 
(Tecan, Männedorf, Switzerland). 30µg of total protein was solubilized in loading buffer 
(375mM Tris-HCl pH=6.8, 10% SDS, 50% glycerol, 12.5% β-mercaptoethanol, 0.02% 
bromophenol blue) for 5min at 95°C. Proteins were resolved by 7.5% or 10% SDS-PAGE 
gel (375mM Tris/HCl, 7.5% or 10% acrylamide, 0.1% SDS, 0.05% APS, 0.1% TEMED) at 
100V. 1x running buffer (25mM Tris, 192mM glycine, 0.1% SDS) was used. Gel was 
transferred to nitrocellulose membrane (cat. no.: S80209; Pall Corporation, Dreieich, 
Germany) at 100V for 70min in cooled transfer buffer (25mM Tris, 192mM glycine, 10% 
methanol). The membrane was blocked within 1h at RT with 5% skim milk (cat. no.: 
M7409; Sigma-Aldrich, St. Louis, USA) prepared in 1x TBST (50mM Tris, 150mM NaCl, 
0.1% tween 20). After blocking, the membranes were blotted with specific antibodies 
diluted in 5% skim milk: anti-PDGFRα (1:1000), anti-α-SMA (1:1000), anti-ADRP (1:600) 
and anti-β-actin (1:5000). Antibodies were incubated for 1h or overnight at RT or 4ºC. 
Secondary antibodies (1:3000) were incubated for 45-60min at RT. After antibodies 
incubation, membranes were washed 3x for 10min with 1x TBST. If necessary a stripping 
buffer (cat. no.: 21062; Thermo Scientific, Rockford, USA) was used for 15min at RT. 
Protein expression was detected by chemiluminescence using Supersignal West Femto Max 
Sensitivity substrate (cat. no.: 34096; Thermo Scientific, Rocford, USA) and Lumi-Imager 
Fujifilm LAS-4000 (Tokyo, Japan). Rabbit anti-PDGFRα C-terminal polyclonal antibody 
(cat. no.: SAB4502141), mouse anti-actin α-smooth muscle monoclonal antibody (cat. no.: 
A5228) and mouse anti-β-actin monoclonal antibody (cat. no.: A5316) were purchased 
from Sigma-Aldrich (St. Louis, USA). Rabbit anti-ADRP polyclonal antibody (cat. no.: 
ab52356) was purchased from abcam (Cambridge, USA). Anti-rabbit IgG- peroxidase 
(POD) conjugated secondary antibody was purchase from Thermo Scientific (cat. no.: 
31460; Rockford, USA) and anti-mouse IgG- POD conjugated secondary antibody from 
Sigma-Aldrich (cat. no.: A9917; St. Louis, USA). 
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4.10. Total RNA integrity and quality 
 
RNA integrity was estimated using Agilent 2100 bioanalyzer (serial no.: 
DE24802342, Agilent, Santa Clara, USA) with 2100 Expert software. Agilent RNA 6000 
Pico (cat. no.: 5067-1513) or Nano (cat. no.: 5067-1511) kits were used according to the 
manufacturer’s instruction. RNA integrity number (RIN) was considered as a guidelines of 
RNA integrity. The RIN was estimated by the entire electrophoretic trace of the RNA 
sample (gel images next to the histograms). Smaller 28S/18S ratio values were associated 
with lower RIN, indicating slight RNA degradation.  
 
4.11. MicroRNA TaqMan low density array (TLDA) 
 
Total RNA was purified with RNeasy Micro Kit or RNeasy Mini Kit (cat. no.: 
74004 or 74104 Qiagen; Venlo, Netherlands) according to the manufacturer’s instruction. 
>350ng (suspended in 3µl) of input total RNA was used for cDNA synthesis. If necessary 
the RNA samples were pulled and precipitated with 1:10 3M sodium acetate, pH=5.5 (cat. 
no.: AM9740; Life Technologies, Carlsbad, USA) and 2.5 volume of 100% ethanol within 
20min on ice. Samples were centrifuged for 10min at 13000rpm, 4°C. RNA pellets were 
washed with 75% ethanol and centrifuged for 5min at 13000rpm, 4°C. Pellets were dried at 
RT and dissolved in 4µl of nucleases free water to reach the desirable amount of 
concentrated RNA. RNA concentration was measured using Qubit 2.0 Fluorometer (cat. 
no.: Q32866) and Qubit RNA Assay Kit (cat. no.: Q32852) obtained from Life 
Technologies, Carlsbad, USA. cDNA was synthesized using TaqMan® MicroRNA 
Reverse Transcription Kit (cat. no.: PN 4366596) and Megaplex™ RT Primers Rodent Pool 
Set v3.0, pools A and B (cat. no.: 4444746) from Applied Biosystems (Foster City, USA) 
according to the manufacturer’s instructions. Megaplex™ RT Primers were designed to 
convert mature miRNAs into cDNA. Eppendorf Mastercycler ep Gradient S thermal cycler 
(Eppendorf, Hamburg, Germany) was used. 
cDNA synthesis thermal-cycling conditions (reaction volume 7,5µl): 
1: 16°C for 2min 
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2: 42°C for 1min 
3: 50°C for 1sec 
4: GO TO step 1, 40 cycles 
5: 85°C for 5min 
6: 4°C hold 
The cDNA was stored at -20°C.  
 
TaqMan microRNA real time PCR arrays were performed using 384-well plate 
TaqMan® Array Rodent MicroRNA A+B Cards Set v3.0 (cat. no.: 4444909) and 
TaqMan® Universal PCR Master Mix II, No AmpErase® UNG, 2x (cat. no.: PN 4324018) 
from Applied Biosystems (Foster City, USA) according to the manufacturer’s instructions. 
Comprehensive coverage of Sanger miRBase v15 was enabled across a two-card set of 
TaqMan® Array MicroRNA Cards (Cards A and B) for a total of 641 (mouse) and 373 (rat) 
unique assays. Card A array v2.0 and card B array v3.0, each contains 384 TaqMan® 
MicroRNA assays, enabling accurate quantitation of 335 (card A) and 306 (card B) unique 
microRNAs for mouse (remaining miRNAs consist of human and rat specific but identified 
in mouse as well). Together 750 specific miRNAs excluding controls were analyzed. On 
each card three mouse endogenous control assays (4x mammalian U6 snRNA, mouse 
specific snoRNA135 and snoRNA202, rat specific Y1 and U87) to aid in data 
normalization, and one assay not related to mammalian as a negative control (Arabidopsis 
thaliana ath-miR159a) were included. Card A contains better characterized miRNAs, while 
Card B contains many of the more recently discovered miRNAs along with the miR* 
sequences.  
The TaqMan low density arrays were performed in collaboration with Prof. Dr. 
Bernd Schmeck and Dr. Wilhelm Bertrams at Department of Molecular Pneumology of 
Philipps University in Marburg. The Applied Biosystems® ViiA™ 7 Real-Time PCR 
System with TaqMan® Array Block (Low Density Array Thermal Cycling Block) and SDS 
software v2.1 (cat. no.: 4453537) was used. Each card was run in triplicates.  
Each miRNA Ct value was normalized to 4x mammalian U6 snRNA, and calculated 
as follow: Average(not normed value U6snRNA_1, not normed value U6snRNA_2, not 
normed value U6snRNA_3, not normed value U6snRNA_4) - not normed value of miRNA 
of interest = ΔCt. All significant candidates from card A&B were showed as a median from 
Materials and Methods 
41 
 
3 replicates. Heat map visualization and hierachical clustering was performed using Perseus 
software version 1.4.0.2. One-way ANOVA test was used; differences were considered 
statistically significant at p<0.05. Data analyses were performed in collaboration with 
biostatistician Dr. Mario Looso from Max Planck Institute in Bad Nauheim. 
 
4.12. Next-Generation Sequencing 
 
Next-Generation Sequencing was performed using Ion Proton™ System (includes 
Ion Proton™ Sequencer and Ion Proton™ Torrent Server) (cat. no.: 4476610; Life 
Technologies, Carlsbad, USA). Total RNA was purified with RNeasy Micro Kit or RNeasy 
Mini Kit (cat. no.: 74004 or 74104 Qiagen; Venlo, Netherlands) according to the 
manufacturer’s instruction. Ribosomal RNA (cytoplasmic and mitochondrial) was depleted 
using Low Input RiboMinus™ Eukaryote System v2 (cat. no.: A15027; Life Technologies, 
Carlsbad, USA) according to the manufacturer’s instruction. RiboMinus™-enriched RNA 
samples were fragmented by RNaseIII to the desired size of 100-200bp fragments and 
transcribed into cDNA using Ion Total RNA-Seq Kit v2 (cat. no.: 4475936; Life 
Technologies, Carlsbad, USA) according to the manufacturer’s instruction. Each cDNA 
library was created from 2 combined RNA samples (according to Figure 12). The Ion PI™ 
Template OT2 200 Kit v2 (cat. no.: 4485146; Life Technologies, Carlsbad, USA) was used 
for template preparation. Templated Ion PI™ Ion Sphere™ particles were prepared for  
sequencing runs by use of Ion PI™ Sequencing 200 Kit v2 (cat. no.: 4485149; Life 
Technologies, Carlsbad, USA) and further deposited in Ion PI™V2 chips (cat. no.: 
4482321; Life Technologies, Carlsbad, USA). The sequencing quality control and 
replicates correlation were performed. 
Differential expression of isoforms of the respective samples was analyzed using the 
TopHat-Cuffdiff pipeline: 
1. Creation of a Bowtie 2 genome index for reference mouse assembly version mm9 
(NCBIM37) 
2. Alignments of RNA-Seq reads to the genome to identify exon-exon splice junctions 
using TopHat including annotation from the NCBI Annotation Release 103 
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3. Reference-guided assembly of RNA-Seq reads into transcripts and report of abundance 
estimates (RPKM/FPKM) using Cufflinks 
4. Comparison of assembled transcripts with a reference annotation, or across experiments, 
using Cuffcompare 
5. Identification of statistically significant differences in transcript expression using 
Cuffdiff2. 
All tools were run with default parameters. The final lists were filtered for a minimum FDR 
(false discovery rate) < 0.05 and log2FC (fold change) <> -1/1. 
FPKM = Fragments Per Kilobase of transcript per Million mapped reads,  
FPKMx = FPKM of the gene in sample x; FPKMy = FPKM of the gene in sample y;  
log2(FPKMy/FPKMx) = the (base 2) log of the fold change y/x 
q-value = the FDR-adjusted p-value of the test statistic after Benjamini-Hochberg 
correction for multiple-testing. 
 
 
Figure 12 Scheme of PDGFRα-positive cells transcriptome sequencing experiment setup. Three 
RNA samples were used for each time point (W6, P5) and negative control (cells from whole lung 
homogenate without CD45- and PDGFRα-positive cells). One cDNA library was prepared from 
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two samples. Two independent cDNA libraries from each time points or NC were loaded on the 
chips. NC = negative control. 
Next generation sequencing was performed by Dr. Stefan Günther within the 
ECCPS Next-generation sequencing and bioinformatics platform at the Max Planck 
Institute in Bad Nauheim. Analysis of the data was done in collaboration with 
biostatisticians Dr. Carsten Künne and Dr. Mario Looso from Max Planck Institute in Bad 
Nauheim/ ECCPS Next generation sequencing and bioinformatics platform. 
 
4.13. Statistical analysis 
 
The results were shown as mean ± SEM for each condition unless otherwise stated 
in description. Significance of the parametric differences among more than 2 groups was 
evaluated using one-way ANOVA and between 2 groups with Student's t-test using 
GraphPad Prism 5 (GraphPad Software, Inc., USA) or Microsoft Excel 2010 (Microsoft, 
Redmond, USA) respectively. All experiments were repeated at least 3 times, and 
representative experiments were shown. Differences were considered statistically 
significant at p<0.05. Pictures were assembled using ImageJ 1.46r. Representative pictures 
of at least 3-times repeated experiments are shown. 
 
4.14. Computational analysis 
 
 For the computational data analyses the following software (algorithms) was used: 
a) TargetScan Release 5.2: prediction of miRNA targets database developed at Whitehead 
Institute for Biomedical Research. 
b) miRTarBase Release 4.4: experimentally validated microRNA-target interactions 
database; Department of Biological Science and Technology, Institute of 
Bioinformatics and Systems Biology, National Chiao Tung University, Hsinchu, 
Taiwan [50]. 
c) Ingenuity Pathway Analysis (IPA): allows exploring, interpreting, and analyzing 
complex biological systems. MiRNA functions and molecular interactions analysis 
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were based on experimentally observed datasets (based on number of reviewed 
publications). P-values were generated for each function using Fisher’s exact test. 
Citing: Ingenuity® Systems, www.ingenuity.com. 
d) GOrilla (updated March 8th 2013): a tool for identifying and visualizing enriched gene 
ontology (GO) terms in ranked lists of genes. Components of the GOrilla system were 
designed as part of the European Union FP6 funded Multi Knowledge Project [36]. 
e) Molecular Signatures Database (MSigDB) v4.0, updated May 31, 2013: collection of 
annotated gene sets for use with Gene Set Enrichment Analysis (GSEA) software. 
GSEA is a computational analysis of the overlaps between experimental gene set and 
gene sets in MSigDB. The gene sets are curated from the following online databases:  
Name URL/Reference 
KEGG (Kyoto Encyclopedia of Genes and Genomes) http://www.genome.jp/kegg 
Pathway Interaction Database (PID) http://pid.nci.nih.gov 
Reactome http://www.reactome.org 
BioCarta http://www.biocarta.com 
Signal Transduction KE (ST) http://stke.sciencemag.org 
Signaling Gateway http://www.signaling-gateway.org 
 
GSEA is a method that determines whether an a priori defined set of genes shows 
statistically significant differences between two biological states concerning their 
differential expression (phenotypes, time points, etc.). It considers experiments with 
genome-wide expression profiles from samples belonging to two classes. Enrichment score 
(ES) reflects the degree to which a gene set is overrepresented at the extremes (top or 
bottom) of the entire ranked list. The score is calculated by walking down the list, 
increasing a running-sum statistic when a gene is encountered in one gene set (correlated 
with phenotype) and decreasing it when genes are not encountered in this gene set. The ES 
must be adjusted to account for differences in the gene set sizes. Gene sets that are in the 
middle of ranked list i.e. are not specific for one phenotype are accounted in an additional 
step of normalization (ES is normalized by accounting the size of each gene set). Therefore, 
a normalized enrichment score (NES) allows to compare analysis results across gene sets. 
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Leading edge gene subsets show gene members that contribute most to the enrichment 
score (after or before the peak of enrichment score). The nominal p-values need to be 
corrected to adjust for multiple hypothesis testing. False positives results are controlled by 
calculating the false discovery rate (FDR) corresponding to each NES. The FDR stands for 
the estimated probability that a set with a given NES represents a false positive finding. It is 
computed by comparing the tails of the observed and null distributions for the NES. A 
significantly enriched gene set is considered if its NES has an FDR q-value below 0.25 or 
the family wise error rate (FREW; probability of making one or more false discoveries) is 
<0.05. The statistical stringency of FREW is higher than FDR (q-value). Gene Set 
Enrichment Analysis (GSEA) was developed at the Broad Institute of MIT and Harvard 
[92]. 
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Chapter 5 
RESULTS 
 
5.1. Characterization of fibroblasts subsets in lung tissue 
 
Based on specific phenotypic markers of previously identified lung fibroblasts 
subsets, their temporal and spatial expression pattern was evaluated within wild type or 
transgenic mice lung tissue across different postnatal time points (P3, P5, P7, P10, P14) and 
in adult (W8) mice (Figure 13). ADRP, the phenotypic marker of lipofibroblast was 
linearly down-regulated during postnatal lung development and slightly detectable in adult 
tissue (Figure 13). ADRP-positive cells were co-stained with vimentin (fibroblast marker), 
CD31 (endothelial cell marker) and CD45 (leukocyte marker). ADRP protein was depicted 
as numerous small dots within whole lung tissue besides the bronchial epithelium and the 
endothelium of big vessels (Figure 14A). Wild type mouse PDGFRα-positive cells were 
present within the alveolar interstitial tissue, around the bronchi and the adventitial space of 
the vessels (Figure 13). Transgenic PDGFRα-GFP-positive cells were co-stained with 
ADRP, αSMA (myofibroblast and smooth muscle cells marker), CD31, cytokeratin (CK; 
epithelium marker), and CD45 (Figure 15). PDGFRα-GFP-positive cells moderately co-
expressed αSMA at P3 and highly at P14 but not in adult lung tissue. Moreover, PDGFRα-
GFP-positive cells surrounding the bronchi expressed GFP on a lower level (dim) than in 
the alveolar interstitial walls (bright). αSMA expression abundantly increased after P5 and 
peaked between P7-P10 and then again decreased at P14. In the adult lung tissue, αSMA 
expression level was almost undetectable in the interstitium but still highly expressed 
around the vessels and bronchi (Figure 13). Additionally, smMHC/CreER-mT/mG and 
smMHC/Cre/eGFP transgenic mice lung tissues were used to identify myofibroblasts 
localization (Figure 14C). αSMA and SMMHC (mGFP- or eGFP-tagged) proteins were 
localized at the tips of the newly forming secondary septa and around the alveolar rings 
(Figure 14B). Isotype controls for primary and secondary antibodies were used for each 
staining (Appendix, Figure A2). 
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Figure 13 Temporal and spatial expression patter of lung fibroblasts subsets during postnatal 
developmental time points and in adult mice. Wild type mouse lung tissue was fluorescently 
stained with antibodies against ADRP (yellow), PDGFRα (green) and αSMA (red) at postnatal day 
3, 5, 7, 10, 14 and week 8. Isotype control was used to adjust fluorescent intensity for each marker. 
Anti -ADRP, - PDGFRα and - αSMA/Cy3 primary antibodies were used. Alexa fluor 488 secondary 
antibody was used. Nuclei were stained with To-Pro3 or Sytox blue. Scale bar = 50µm. 
Results 
48 
 
 
Figure 14 Localization of lipofibroblast and myofibroblast markers in postnatal mouse lung 
tissue (WT). Anti -ADRP -vimentin, -CD31 and -CD45, -αSMA/Cy3, -CK primary antibodies were 
used. Alexa fluor 555 or 488 secondary antibodies were used. Nuclei were stained with To-Pro3 
(blue). Scale bar = 50µm. Isotype controls are shown in Appendix, Figure A2. A) ADRP (yellow) is 
localized within whole lung tissue as small dots surrounding lipid droplets; it is not expressed by 
bronchial epithelium (*) but positively co-expressed by some CD45- (red) and vimentin- (red) 
positive cells (arrows). B) αSMA (red) is localized around vessels (*) and bronchi/bronchioles (#) 
as well as in the interstitium. In the interstitium it is localized at the tips of newly formed septa 
(arrows) and around the alveolar rings (arrow head) C) Tissue from double transgenic 
smMHC/CreER-mT/mG (P8) mouse lung is shown; SMMHC-positive cells (green) turned from red 
(mT) into green (mGFP) after tamoxifen-induced CreER-loxP recombination; SMMHC-negative 
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cells remained red. SmMHC/Cre/eGFP (P14) transgenic mouse lung tissue was co-stained with 
ADRP (red). SmMHC localization is similar to αSMA. Anti -GFP/FITC antibody was used.  
 
Figure 15 Localization of PDGFRα-positive cells in lung tissue. PDGFRα-GFP transgenic mouse 
were used. PDGFRα-positive cells (green) are present in interstitium as well as parabronchial and 
adventitial space. Anti-GFP/FITC antibody was used to increase GFP signal expressed in the cell 
nuclei. Anti -αSMA/Cy3 (red), -ADRP (yellow or red), -CD31 (red), -CK (red) and -CD45 (red) 
primary antibodies and Alexa Fluor 555 secondary antibody were used.  Nuclei were stained with 
To-Pro3 (blue). Scale bar = 50µm. Ad = adult. Isotype controls are shown in Appendix, Figure A2. 
 Fibroblasts subsets phenotypic markers expression intensities were measured on 
gene and protein levels in whole lung homogenate. The mean of protein/β-actin 
densitometric ratio is shown on bar chart (Figure 16A). Expression patterns of ADRP, 
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αSMA (αSMactin) and PDGFRα proteins were similar to those obtained by tissue 
immunostaining (Figure 13). All three proteins were down-regulated in the adult mouse 
lung (week 8). ADRP protein expression level peaked at P5, αSMA at P10 and PDGFRα 
was highest at P2 then down-regulated at P5 and again slightly up-regulated. Replicates of 
protein blots from different littermates (2-5 animals) are also presented (Figure 16B). 
αSMA expression level obtained from each replicate was highly variable at P5, P10 and 
P14. 
 
 
Figure 16 Protein expression levels in whole lung homogenate during different postnatal lung 
developmental time points. A) Each bar shows mean ± SEM of protein/β-actin densitometric ratio 
from three (n=3) replicates (independent groups of animals, n= 2-5). One-way ANOVA 
(Bonferroni’s post-test) was applied; p<0.05; statistically significant were considered: ADRP for: 
*P2 vs. P5, *P2 vs. W8, #P5 vs. P10, #P5 vs. P14, #P5 vs. W8, §P10 vs. W8. B) Replicated protein 
blots from different littermates are shown. Molecular mass of each protein is indicated as kDa. β-
actin as loading control was used. P= postnatal day, W= week after birth. 
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Expression level of Adrp, Smmhc (approved gene symbol: MYH11) and Pdgfrα 
genes was evaluated using real time PCR and normalized to Pbgd housekeeping gene 
(Figure 17). Adrp was regulated on a much higher level than Smmhc and Pdgfrα. Pdgfrα 
was significantly up-regulated at P14 and in the adult tissue (week 8) comparing to P2. 
Adrp was significantly up-regulated at P14 and W8 vs. P2, P5 and P10. Similar to the 
αSMA protein expression level, Smmhc peaked at P10 and its expression level showed high 
variability between the replicates.  
 
Figure 17 Gene expression levels in whole lung homogenate during different postnatal lung 
developmental time points. Scatter plot chart shows expression level of Adrp, Smmhc and Pdgfrα 
normalized to Pbgd housekeeping gene (∆Ct = housekeeping gene – target gene). Four (N=4) 
independent groups of animals (n= 2-5 littermate) were used for each time point. One-way ANOVA 
(Newman-Keuls test) was applied; p<0.05; statistically significant were considered: pdgfrα: *P2 
vs. P14, *P2 vs. W8; adrp: *P2 vs. P14, *P2 vs. W8, #P5 vs. P14, #P5 vs. W8, ^P10 vs. P14, ^P10 
vs. W8. Each single symbol (square, triangle or rhombus) indicate ∆Ct value from independent 
replicate. 
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5.2. Characterization of myofibroblasts and lipofibroblasts in cell 
culture 
 
Primary cells from lung homogenate were cultured in standard conditions and the 
fibroblasts phenotype was investigated after 1 or 2 days (Figure 18). Cells from postnatal 
day 6 (P6) and adult (W8) mouse lungs were co-stained with anti -αSM actin and anti -
ADRP antibodies. After 1 day in cell culture, the cells from P6 lung were differentiated into 
αSM actin positive (αSM actin+) myofibroblasts that co-expressed ADRP, and cells that 
expressed only ADRP. Cells isolated from the adult mouse lung differentiated into 
myofibroblast much slower than those from P6 and did not co-express ADRP after 1 day in 
cell culture. However the ADRP-single positive cells were present in the culture obtained 
from adult mouse. After 2 days of culture, almost all fibroblasts from the P6 lung were 
differentiated into double positive αSM actin+ ADRP+ cells. Myofibroblasts from adult lung 
also co-expressed ADRP at day 2. Isotype controls for primary and secondary antibodies 
were used (Appendix, Figure A1). 
 
 
Figure 18 ADRP and αSM actin expression pattern in lung primary fibroblasts from WT mouse 
lungs after 1 and 2 days (1d and 2d) in standard cell culture. Cells were isolated from postnatal 
day 6 (P6) or adult animals. Cells obtained from postnatal day 6 lung possess stronger 
Results 
53 
 
differentiation capacities than cells from adult lung. Pictures are shown in merge, αSM actin in red, 
ADRP in green, and nuclei in blue (DAPI). Anti –αSM actin/Cy3, -ADRP primary antibodies and 
AF 488 secondary antibody were used. Observation was repeated more than 3 times at the same 
conditions. Scale bar = 30 µm. Isotype controls for primary and secondary antibodies are shown in 
Appendix, Figure A1. 
 
5.3. Characterization of PDGFRα-positive fibroblasts in cell culture 
 
To analyze the phenotype of PDGFRα-positive cells, PDGFRα-GFP transgenic 
mice were used. Lung primary cells from postnatal day 5 (P5) were cultured 3 days in 
standard conditions. Cells were stained with anti -αSM actin, -collagen I (Col I), -CD45, -
ADRP, and -cytokeratin (CK) antibodies. PDGFRα-positive cells (GFP- tagged nuclei) co-
expressed αSM actin, collagen I and ADRP but not CD45 and cytokeratin (Figure 19).  
PDGFRα-positive cells were analyzed during their differentiation process into 
myofibroblasts in cell culture conditions. Observed changes of the PDGFRα expression 
level during the cell differentiation were based on GFP expression intensity level (Figure 
20). The GFP intensity level was in average of 2.4-fold change lower in differentiated cells 
(cultured longer, 72 hours) than in undifferentiated cells (cultured 2 hours or 24hours) 
(Figure 20B). The GFP intensity was measured from 3 different wells of a chamber slide 
for each time point as an average intensity of the pixels in the marked area (green nuclei) 
using ImageJ. After 2 or 24 hours GFP protein expression intensity (bright) was more 
heterogeneous than after 72 hours with more homogenous expression level (dim). GFP 
intensity decreased accordingly with αSM actin cytoskeleton formation and cell size growth 
(Figure 20A). ADRP was expressed in both PDGFRα-GFPbright+ and PDGFRα-GFPdim+ 
cells (Figure 20).  
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Figure 19 Phenotype of PDGFRα-positive cells. Cells were obtained from a PDGFRα-GFP 
transgenic mouse at postnatal day 5 (P5). Cells were cultured 3 days (3d) in standard conditions. 
PDGFRα-positive cells are shown as GFP-positive (green). GFP-positive cells co-expressed αSMA, 
Col I and ADRP but not CD45 and CK. Anti -GFP/FITC, -αSM actin (αSMA)/Cy3, -collagen I (Col 
I), -cytokeratin (CK), -ADRP and -CD45 primary antibodies were used. Alexa Fluor 555 secondary 
antibody was used. Cell nuclei were stained with DAPI. Scale bar = 100µm. Isotype controls for 
primary and secondary antibodies are shown in Appendix, Figure A1. 
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Figure 20 Changes of PDGFRα expression level intensity during PDGFRα-GFP-positive cells 
differentiation. A) PDGFRα expression level was evaluated based on GFP intensity. Cells from 
week (W6) mice were cultured 2 hours (2h), 24 hours (24h) and 72 hours (72h). Anti -GFP/FITC, -
ADRP, -αSM actin/Cy3 primary antibodies, and AF 555 secondary antibody were used. Insets show 
GFP
+
 nuclei. Nuclei were stained with DAPI. Scale bar = 30µm. Isotype controls for primary and 
secondary antibodies are shown in Appendix, Figure A1. B) Average intensity of the pixels in the 
marked area (GFP-positive nuclei showed in inset) was measured using ImageJ. GFP intensity at 
different time points in cell culture was measured from 3 independent pictures taken with the same 
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microscope settings. Scatter plot graphs with mean +/- SEM are shown. Student's t-test, p<0.05 
was applied. *** p≤0.001.  
Cells isolated from P5 wild type mouse lungs were cultured 2 days and co-stained 
with anti -αSM actin and anti -PDGFRα antibodies (Figure 21). Fully differentiated αSM 
actin
+
 myofibroblasts were PDGFRα-negative. Undifferentiated PDGFRαbright+ fibroblasts 
with long thin cytoplasmic extensions (filopodia) were starting to co-express αSM actin 
with very high intensity and forming α-actin cytoskeleton.  
 
 
Figure 21 Differentiation of PDGFRα-positive fibroblast into myofibroblast. Cells were isolated 
from WT P5 mouse lung homogenate. After 2 days in culture, cells were co-stained with anti- αSM 
actin/Cy3 and anti- PDGFRα primary antibodies. Undifferentiated PDGFRαbright+ cells co-
expressed αSM-actin with high expression intensity (arrow). Fully differentiated myofibroblast were 
αSM actin-positive but not PDGFRα-positive. AF 488 secondary antibody was used to detect anti- 
PDGFRα primary antibody. Nuclei were stained with DAPI. Experiment was repeated at least 3 
times at the same conditions. Scale bar = 30µm. Isotype controls for primary and secondary 
antibodies are shown in Appendix, Figure A1. 
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5.4. Fluorescence-activated cell sorting (FACS) of PDGFRα-positive 
cells 
 
 Cells isolated from PDGFRα-GFP transgenic mice were subjected to FACSorting 
(Figure 22). GFP-positive cells from postnatal day 5 mice constituted ~9% of the total cell 
number and consisted of 2 subpopulations: PDGFRα-GFPdim (0.7% of total cells; Figure 
22, upper panel) and PDGFRα-GFPbright (high) (8.2% of total cells; Figure 22, upper panel). 
GFP-positive cells obtained from mice 6 weeks after birth consisted of 1 population with 
very high GFP expression level and constituted ~3.2% of the total cell number (Figure 22, 
lower panel). Repeated post-sorting analysis of GFP-positive cells revealed a purity of ~96-
98% and a viability of ~55-80% (Figure 22, middle panel). Though PDGFRα-GFP+ sorted 
cells showed a high purity they did not show a sufficient viability. Thus the RNA quality 
was not sufficient to continue with the further experiments of miRNA and mRNA profiling. 
Hence, a different cell isolation technique was chosen (Section 5.5.). 
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Figure 22 FACSorting of PDGFRα-GFP-positive cells from postnatal day 5 (P5) and week 6 
(W6) lungs. Cells were gated in the FSC-A vs. SSC-A channels to eliminate autofluorescent debris. 
The FSC-H vs. FSC-W and the SSC-A vs. SSC-H were used to depict doublet/aggregate 
discrimination. Upper panel shows cells sorted from P5 lungs. GFP-positive cells were gated as 
“dim” or “bright (high)” subpopulations. Middle panel shows post sorting of cells from P5 lungs. 
Viability was measured by counting the incorporation of sytox blue into dead cells, middle panel 
upper part. Cell purity is shown in the middle panel lower part. Lower panel shows cells sorted 
from W6 lungs where GFP-positive cells were gated as “bright (high)”. BD FACSDiva™ software 
v6.1.3 was used. 
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5.5. PDGFRα-positive cells separation by the use of magnetic 
Dynabeads 
 
The isolation of PDGFRα-GFP-positive cells using the magnetic Dynabeads 
technique was chosen as alternative method for the previous described FACSorting of 
PDGFRα-positive cells (Section 5.4). To verify the beads positive sorting and purity, 
PDGFRα-GFP-positive cells were used. Sorted cells were cultured in standard conditions 
and visualized as GFP-positive cells surrounded by magnetic beads (Figure 23). Magnetic 
beads sorted cells were counted using Neubauer chamber. The number of GFP-positive 
cells was calculated as percentage of the total cell number sorted by use of magnetic beads. 
The obtained cell subset purity was ~ 85-90%.  
 
Figure 23 PDGFRα-GFP-positive cells separation based on magnetic bead sorting. Sheep anti-rat 
magnetic beads were coupled with a rat anti -PDGFRα antibody. Positively sorted cells were 
culture 2 days in standard conditions; GFP-positive cells are surrounded by magnetic beads. Anti-
GFP/FITC antibody was used. Nuclei were stained with DAPI. Scale bare = 50µm. 
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5.6. Integrity and quality of PDGFRα-positive cells total RNA 
 
The integrity of total RNA was evaluated using a bioanalyzer instrument. The RNA 
integrity number (RIN) ranged approximately from 7-8, whereas the ratio of 28S/18S 
rRNA subunit varied approximately from 1.3-2.5 (Figure 24, representative graphs). The 
RNA quality was considered as good enough for further miRNome analysis.  
 
Figure 24 Total RNA integrity of sorted PDGFRα-positive cells. The peaks of 28S and 18S rRNA 
subunits are marked on the histograms and visualized on gel images as darker bands (see also 
Figure 30). Y-axis shows fluorescence units (FU), x-axis shows time in seconds [s]. Marker is 
indicated as a green band on the gel image. Eukaryote total RNA Nano Kit was used. RIN = RNA 
Integrity Number. 
 
5.7. MicroRNA expression profiles of pulmonary PDGFRα-positive 
cells across different time points of lung development 
 
PDGFRα-positive cells miRNA expression profiles across four different time points 
of lung development (E16.5, P5, P14 and W6) were generated by TaqMan low density 
array. Two array cards were used; card A and card B (see 4.11.). From 750 miRNAs only 
98 were significantly regulated across four time points (one-way ANOVA test; p<0.05). 
The miRNA expression levels are presented on a heat map (Figure 25). A hierarchical 
clustering algorithm was used to visualize similarities of the expression patterns between 
these 98 regulated miRNAs. 2 major clusters were extracted. The upper cluster “1” with 
highly expressed miRNAs (brighter yellow) and the lower cluster “2” with general lower 
expression level across time points (darker blue and darker yellow). K-means clustering 
Results 
61 
 
algorithm with a solution of 30 clusters was used to generate the most cohesive clusters 
with randomly chosen centroids. Generated clusters are shown on line-plot graphs (Figure 
26). The background grey lines indicate all 98 significantly regulated miRNAs and the red 
lines members of specific clusters (Table 2). 5 of these clusters were nearly linearly down-
regulated (cluster 4, 5, 10, 13, 19) and 3 up-regulated (cluster 7, 16, 18) across four 
developmental time points. Some of the clusters’ members expression levels (down- or up-
regulated) peaked at P5 (cluster 0, 27) or P14 (cluster 9, 27) or the expression was 
constantly down-regulated across P5, P14 and W6 (cluster 14) and P14, W6 (cluster 2, 29). 
56 of these miRNAs were up-regulated at P5 compared to W6 and only 16 miRNAs at W6 
vs. P5 (Table 3). Remaining miRNAs were expressed at the similar level at P5 and W6.  
Using the Ingenuity Pathway Analysis (IPA) system, we could identified some of 
the biological functions and diseases in which the miRNAs up-regulated at P5 vs. W6 and 
W6 vs. P5 are involved (only experimentally validated) (Figure 27). MiRNAs up-regulated 
at W6 vs. P5 were highly associated with inflammatory response, immunological diseases, 
respiratory diseases and connective tissue disorders, whereas miRNAs up-regulated at P5 
vs.W6 were found to be related with cellular development, tissue development, embryonic 
development, respiratory system and connective tissue development. Though there was no 
difference between P5 and W6 when it comes to regulation of bio-functions like cell 
functionality, basic cell biology and morphology. 
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Figure 25 Expression pattern of miRNAs across different time points of lung development. 
Differentially regulated miRNAs across 4 time points are shown on the heat map as median of 3 
replicates for each time point; yellow– high expression level, blue– low expression level. 
Hierarchical clustering indicates similarities of expression level between different miRNAs across 
the time points. Single miRNAs of selected clusters are listed in Table 2. One-way ANOVA test, 
p<0.05 was applied. Data analysis was performed in collaboration with Dr. Mario Looso from Max 
Planck Institute in Bad Nauheim. Data was generated and collected at Department of Molecular 
Pneumology of Philipps University in Marburg (collaborators: Prof. Dr. Bernd Schmeck and Dr. 
Wilhelm Bertrams). E= embryonic day, P= postnatal day, W= week. 
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Figure 26 Expression pattern of miRNAs within specific clusters. MiRNAs were grouped 
according to their expression level similarities across different time points. Grey line plots indicate 
all 98 significantly regulated miRNAs and red line plots the miRNA members of specific clusters. K-
means clustering algorithm was used. Y-axis shows ΔCt values. Data was analyzed in collaboration 
with Dr. Mario Looso from Max Planck Institute in Bad Nauheim. E= embryonic day, P = 
postnatal day, W = week after birth. 
Table 2 List of miRNA members within their clusters. P-values are shown. ANOVA test; 
p<0.05. 
 
 
 
CLUSTER miRNAs p-value CLUSTER miRNAs p-value 
Cluster 0 mmu-miR-666-5p 0.0041 Cluster15 
 
mmu-miR-370 
mmu-miR-433 
 mmu-miR-434-5p 
mmu-miR-487b 
mmu-miR-495 
mmu-miR-337 
mmu-miR-487b 
mmu-miR-541 
mmu-miR-543 
rno-miR-350 
rno-miR-551B 
0.0009 
0.0030 
3.35E-09 
0.0010 
0.0004 
0.0014 
3.15E-08 
1.78E-09 
0.0046 
0.0021 
0.0094 
Cluster2 mmu-miR-543 
mmu-miR-299 
mmu-miR-376a* 
mmu-miR-673-3p 
0.0040 
2.67E-07 
0.0031 
0.0027 
Cluster16 
 
mmu-miR-30d 
mmu-miR-146a 
mmu-miR-146b 
mmu-miR-150 
mmu-miR-222 
mmu-miR-29a 
rno-miR-146B 
0.0062 
1.14E-09 
0.0012 
3.75E-09 
0.0013 
0.0001 
0.0004 
Cluster 4 hsa-miR-421 
mmu-miR-1939 
mmu-miR-674* 
5.42E-09 
0.0104 
0.0091 
Cluster 17 mmu-miR-369-5p 0.0095 
Cluster5 
 
mmu-miR-323-3p 
mmu-miR-410 
mmu-miR-130b* 
mmu-miR-376b* 
0.0060 
0.0001 
0.0012 
0.0022 
Cluster18 
 
mmu-miR-126-3p 
mmu-miR-223 
hsa-miR-200c 
hsa-miR-223 
0.0070 
0.0102 
0.0104 
0.0001 
Cluster6 mmu-miR-805 0.0135 Cluster19 
 
mmu-miR-127 
mmu-miR-193b 
mmu-miR-296-5p 
mmu-miR-335-3p 
mmu-miR-335-5p 
rno-miR-351 
mmu-miR-411 
hsa-miR-149 
hsa-miR-93* 
mmu-miR-1839-3p 
mmu-miR-322* 
mmu-miR-322 
mmu-miR-503* 
rno-miR-20b 
0.0023 
0.0034 
0.0028 
0.0001 
0.0030 
0.0007 
0.0009 
0.0024 
0.0077 
0.0002 
0.0021 
0.0042 
0.0009 
0.0102 
Cluster 7 
 
mmu-miR-29c 
mmu-miR-139-5p 
mmu-miR-155 
mmu-miR-34c* 
0.0009 
0.0021 
0.0051 
0.0028 
Cluster20 
 
mmu-miR-126-5p 
mmu-miR-92a 
hsa-miR-200b 
mmu-miR-374-5p 
0.0109 
0.0107 
0.0023 
0.0015 
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Table 3 MiRNAs up-regulated at P5 vs. W6 and W6 vs. P5. 
Up-regulated at P5 vs. W6 Up-regulated at W6 vs. P5 
rno-miR-350 
rno-miR-551B 
hsa-miR-421 
mmu-miR-1939 
mmu-miR-674* 
mmu-miR-323-3p 
mmu-miR-410 
mmu-miR-130b* 
mmu-miR-376b 
mmu-miR-668 
hsa-miR-136 
rno-miR-379* 
rno-miR-382* 
mmu-miR-543 
mmu-miR-299 
mmu-miR-376a* 
mmu-miR-673-3p 
mmu-miR-370 
mmu-miR-376a 
hsa-miR-206 
mmu-miR-1904 
mmu-miR-135b 
mmu-miR-376c 
mmu-miR-379 
mmu-miR-382 
mmu-miR-409-3p 
mmu-miR-434-3p 
hsa-miR-214* 
hsa-miR-455 
mmu-miR-449b 
rno-miR-409-3P 
mmu-miR-127 
mmu-miR-193b 
mmu-miR-296-5p 
mmu-miR-335-3p 
mmu-miR-335-5p 
rno-miR-351 
mmu-miR-411 
hsa-miR-149 
hsa-miR-93* 
mmu-miR-1839-3p 
mmu-miR-322* 
mmu-miR-322 
mmu-miR-503* 
rno-miR-20b  
mmu-miR-433 
mmu-miR-434-5p 
mmu-miR-487b 
mmu-miR-495 
mmu-miR-337 
mmu-miR-487b 
mmu-miR-541 
mmu-miR-543 
mmu-miR-204 
mmu-miR-369-5p 
mmu-miR-30d 
mmu-miR-146a 
mmu-miR-146b 
mmu-miR-150 
mmu-miR-222 
mmu-miR-29a 
rno-miR-146B 
mmu-miR-126-3p 
mmu-miR-223 
hsa-miR-200c 
hsa-miR-223 
mmu-miR-29c 
mmu-miR-139-5p 
mmu-miR-155 
mmu-miR-34c* 
rno-miR-664 
 rno-miR-664 0.0014    
Cluster 8 mmu-miR-451 0.0133 Cluster 22 
 
mmu-miR-204 
mmu-miR-376a 
mmu-miR-376b 
hsa-miR-206 
0.0070 
0.0116 
0.0050 
0.0019 
Cluster 9 mmu-miR-1904 0.0003 Cluster24 mmu-miR-463 0.0060 
Cluster 10 
 
mmu-miR-135b 
mmu-miR-376c 
mmu-miR-379 
mmu-miR-382 
mmu-miR-409-3p 
mmu-miR-434-3p 
hsa-miR-214* 
hsa-miR-455 
mmu-miR-449b 
rno-miR-409-3P 
Y1 
0.0019 
0.0020 
0.0116 
0.0014 
0.0006 
0.0014 
0.0007 
0.0047 
0.0017 
6.50E-06 
0.0072 
Cluster25 
 
mmu-miR-29b 
mmu-miR-23a 
mmu-miR-1931 
mmu-miR-1943 
0.0068 
0.0099 
0.0007 
0.0002 
Cluster13 mmu-miR-375 
mmu-miR-532-3p 
0.0032 
0.0099 
Cluster27 mmu-miR-205 
mmu-miR-423-5p 
0.0082 
0.0003 
Cluster14 
 
mmu-miR-329 
rno-miR-758 
rno-miR-219-1-3p 
hsa-miR-154* 
 mmu-miR-1199  
mmu-miR-483* 
mmu-miR-483 
mmu-miR-879* 
0.0063 
0.0067 
0.0006 
0.0009 
8.79E-06 
0.0015 
7.62E-07 
6.24E-05 
Cluster 28 hsa-miR-28-3p 
mmu-miR-31* 
0.0108 
0.0049 
 
   Cluster 29 
 
mmu-miR-668 
hsa-miR-136 
rno-miR-379* 
rno-miR-382* 
0.0072 
0.0133 
0.0079 
0.0058 
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Figure 27 Bio-functions of miRNAs up-regulated at P5 vs. W6 and W6 vs. P5 in pulmonary 
PDGFRα-positive cells. Fisher’s exact test was used, threshold value was set as p<0.05. Data were 
analyzed through the use of IPA (Ingenuity® Systems, www.ingenuity.com). 
 
5.7.1. In silico analysis of miRNAs putatively targeting Pdgfrα 3’-UTR 
 
Using TargetScan algorithm, we identified only 4 from the 98 significantly 
regulated miRNAs that were predicted to target the Pdgfrα gene along the highly conserved 
binding sites for vertebrates, whereas 20 miRNAs were associated with poorly conserved 
binding sites among vertebrates (Table 4). These 4 identified miRNAs belong to clusters: 4 
(hsa-miR-421), 10 (mmu-miR-449b) and 19 (hsa-miR-149, rno-miR-20b); all of them were 
linearly down-regulated across the four time points (E16.5=>W6). Using miRTarBase, we 
identified no miRNAs (within 98 significantly regulated) which were experimentally 
validated to target Pdgfrα. MiR-20b-5p, the member of miR-17-5p family appeared to have 
the highest probability of preferential site conservation within Pdgfrα gene, moreover it 
was found to repress Pparγ and Tgfbr 2 (validated targets).  
 
Table 4 MiRNAs predicted to bind to highly or poorly conserved sites within the Pdgfrα 
3’-UTR gene fragment. MiRNAs were identified by the use of TargetScan Release 5.2. 
Affiliation of miRNAs to clusters according to K-means clustering is shown. C = Cluster.  
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miRNAs binding to highly conserved sites within 
the Pdgfrα 3’-UTR gene fragment 
miRNAs binding to poorly conserved sites within 
the Pdgfrα 3’-UTR gene fragment 
rno-miR-20b-5p (C19; miR-17-5p family) (binding to 
sites with higher probability of preferential 
conservation)  
hsa-miR-149-5p (C19) (conserved only among 
mammals) 
hsa-miR-421 (C4) (conserved only among mammals) 
mmu-miR-449b (C10; mir-34a-5p family) 
mmu-miR-146b (C16), mmu-miR-29a (C16),  
mmu-miR-30d (C16), mmu-miR-150 (C16),  
mmu-miR-223 (C18), mmu-miR-146a (C16),  
hsa-miR-223 (C18), mmu-miR-205 (C27),  
mmu-miR-495 (C15), mmu-miR-370 (C15), 
 mmu-miR-433 (C15), rno-miR-758 (C14) 
hsa-miR-136 (C29), mmu-miR-29b (C25),  
mmu-miR-335-5p (C19), mmu-miR-374-5p (C20), 
mmu-miR-29c (C7), mmu-miR-410 (C5), hsa-miR-
421 (C4), mmu-miR-376c (C10) 
 
MiRNAs binding to the highly or poorly conserved sites on the Pdgfrα 3’-UTR 
gene fragment were further analyzed using Ingenuity Pathway Analysis (IPA). 
Experimentally known or proposed interactions between miRNAs and other molecules 
were generated (Figure 28 A, B). Each miRNA was assigned into and represented as 
miRNA family according to their “seed region” sequence similarity (Appendix, Table A1). 
The network created by miRNAs binding to highly conserved sites within the Pdgfrα 3’-
UTR gene fragment consisted of 2 sub-networks (connected by orange lines on Figure 28). 
They included: 12 transcription regulators (Klf4, Notch1, Runx2, Sirt1, Atf3, Tp53, Ccne1, 
Rb1, E2f1, H2afx, E2f2, E2f3), 1 peptidase (Psen1), 3 enzymes (Mcm3, Dicer1, Dhfr), 1 
transporter (Bcl2), 5 growth factors (Tgfbr2, Cdk7, Met, Cdk5, Cdk4), 1 translation 
regulator (Ago2), 1 phosphatase (Ptpre), 1 pre-mir (let-7), 1 ligand-dependent nuclear 
receptor (Ppara), and 8 other molecules (Creb, Tsc1, Ccnd2, Ccnd1, Ikbip, Birc5, 
Map2k1/2, Rps15). The network formed by miRNAs binding to the poorly conserved sites 
within the Pdgfrα 3’-UTR gene fragment included 3 sub-networks (merged by orange lines 
on Figure 28). They consisted of: 2 transcription regulators (Smad7, Tp53), 1 phosphatase 
(Inppl1), 2 kinases (Mapk14, Chuk), 3 growth factors/ cytokines (Il-8, Ctgf, Bdnf), 1 
enzyme (Dcp2), 1 ligand-dependent nuclear factor (Nr0b2), 1 translation regulator (Ago2), 
6 other molecules (Cofilin, F-actin, Cg, Fsh, Rps15, Mapre2), 7 pre-miRNAs (let-7, pre-
mir-146, -335, -23, -17, -30, -10), and other mature miRs families (miR-20a-3p, -23a-3p, 
Results 
69 
 
let-7a-5p). The full nomenclatures of these molecules are shown in the Appendix, Table 
A2.  
The bio-functions of these miRNAs were also analyzed. MiRNAs binding to the 
poorly conserved sites of the Pdgfrα 3’-UTR gene fragment were associated with cancer, 
inflammatory/infectious diseases, inflammatory response, connective tissue disorder and 
respiratory diseases. MiRNAs binding to the highly conserved sites within the Pdgfrα 3’-
UTR gene fragment were favored to regulate cellular function, cell-to-cell interaction and 
signaling, cell cycle and morphology, cellular growth, proliferation and movement, cell 
death and survival, connective tissue and respiratory system development, embryonic 
development, and tissue development and morphology (Figure 29).  
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Figure 28 Networks of miRNA/molecule interactions associated with A) miRNA binding to the 
highly or B) poorly conserved sites within Pdgfrα 3’-UTR fragment. Interactions between specific 
miRNAs and other molecules are shown as differentially colored lines. Known interactions are 
indicated by solid lines, proposed interactions by dashed lines. MiRNAs discovered in the present 
study to be regulated during lung development in the PDGFRα-positive cells are presented as red. 
Orange lines show the connection between sub-networks. Each MiRNA is labeled as the 
representative of its family with the same “seed region” (see Table 4 and Appendix, Table A1). 
Hsa-miR-149-5p was not experimentally validated to interact with any molecules (A). Data were 
analyzed through the use of IPA (Ingenuity® Systems, www.ingenuity.com). 
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Figure 29 Bio-functions of miRNAs putatively targeting Pdgfrα. MiRNAs were grouped according 
to highly or poorly conserved sites putatively recognized on Pdgfrα 3’-UTR target. Fisher’s exact 
test was used. Threshold value was set as p<0.05. Data were analyzed through the use of IPA 
(Ingenuity® Systems, www.ingenuity.com). 
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5.8. Next-generation sequencing of PDGFRα-positive cells 
transcriptome 
 
All next-generation sequencing procedures were performed by Dr. Stefan Günther 
from Max Planck Institute in Bad Nauheim. Analysis of the data was done in collaboration 
with biostatisticians from Max Planck Institute in Bad Nauheim. 
 
5.8.1. Quality of generated cDNA libraries 
 
cDNA libraries were generated from RNA isolated from postnatal day 5 (P5), week 
6 (W6), and negative control (NC; 1:1 cell from P5 and W6 lung homogenate minus CD45- 
and PDGFRα- positive cells). Total RNA integrity number (RIN) ranged approximately 
from 7-8.5 (Figure 30B). rRNA was depleted and transcriptome RNA concentrated (Figure 
30A). Each library was prepared in duplicate (see section 4.12, Figure 12). No size 
selection of cDNA libraries was performed due to a homogeneous size distribution between 
samples (Figure 31). Samples were then subjected to next-generation sequencing. 
 
5.8.2. Sequencing data quality and depth of coverage 
 
Generated sequencing data were analyzed for the quality and depth of coverage of 
the raw data before trimming. Number of sample bases, Q20 bases, number of reads, mean 
read length was included (Figure 32). The raw data were trimmed to get rid of poor quality 
reads and increase the quality of results. The acceptable threshold was determined for all 
samples during the validation process: min sequence length - 18bp, max sequence length - 
150bp (Table 5). Distribution of sequence length over all sequences before and after 
trimming is shown (Figure 33). Sequence reads were mapped basing on a reference genome 
(mus musculus) by use of TopHat/Bowtie2; percentage of mapped reads is shown (Table 
6). De novo and bad status transcripts were excluded. Replicates (s1/ s2, s3/ s4, s5/ s6) 
concordance measured by Pearson correlation was approximately 93-95% showing good 
reproducibility (Figure 34). Data were further analyzed for differentially regulated genes. 
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Figure 30 Total RNA integrity and rRNA-depleted transcriptome RNA. Eukaryote total RNA Pico 
Kit was used. W6 = week 6, P5 = postnatal day 5, NC = negative control. A) Gel image of total 
RNA trace (line 1, 4, 7) and RNA after rRNA depletion (line 2, 3, 5, 6, 8, 9) are shown. M = marker 
of RNA size. B) Histograms show total RNA trace with the 28S and 18S rRNA peaks. RNA integrity 
number (RIN) is shown. Y-axis shows fluorescence units (FU), x-axis shows number of nucleotides 
[nt].  
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Figure 31 cDNA libraries generated from RNA isolated from lung PDGFRα-positive cells and 
negative control. Histograms show size distribution of cDNA libraries; x-axis shows length of DNA 
fragments in bp; y-axis shows fluorescence units (FU). Gel image for each cDNA library is shown. 
M = marker, W6 = week 6, P5 = postnatal day 5, NC = negative control. Green or purple bands 
indicate max or min size marker. 
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Figure 32 Sequencing data quality and depth of coverage (raw data before trimming). Number of 
sample bases, Q20 bases, number of reads and mean read length are shown. Histograms show 
distribution of reads for each library [bp]. LibI/ II= W6, LibIII/ IV= P5, LibV/ VI= NC. Lib = 
library, NC= negative control, W6 = week 6, P5 = postnatal day 5. 
 
Table 5 Trimmed sequencing data: min length - 18bp, max length - 150bp. Number of 
reads (count) and sample bases (sum) are shown. Lib = library, NC = negative control. 
 
LibI_W6 LibII_W6 LibIII_P5 LibIV_P5 LibV_NC LibVI _NC 
Count 34,136,032 27,728,587 27,521,434 21,511,785 19,967,485 27,833,076 
Sum 3,610,088,275 2,599,105,385 2,851,259,223 2,072,509,720 1,958,138,812 2,702,654,368 
Mean 
Length (bp) 
106 94 104 96 98 97 
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Figure 33 Distribution of sequence length over all sequences. Y-axis shows number of reads. A) 
Raw data, B) trimmed data. 
Table 6 Mapped reads referred to the mus musculus genome. TopHat/Bowtie2 after data 
trimming was used; de novo transcripts and bad status were excluded. Percentage and 
number of mapped reads are shown. Lib = library, NC = negative control. 
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Lib I_w6 Lib II_w6 Lib III_p5 Lib IV_p5 Lib V_ NC Lib VI_ NC 
Mapped 
20240239 
(59.3%) 
14205194 
(51.2%) 
13835536 
(50.3%) 
9633423 
(44.8%) 
13562105 
(67.9%) 
18236745 
(65.5%) 
 
 
Figure 34 Pairwise comparison of global transcripts expression level in sample replicates. The x- 
and y-axes are plotted on a log10-scaled FPKM and show transcripts expression of P5, W6 and NC 
replicates. Pearson correlation is shown. Replicates: s1 W6/ s2 W6; s3 P5/ s4 P5; s5 NC/ s6 NC. 
FPKM = Fragments Per Kilobase of transcript per Million mapped reads, P5 = postnatal day 5, 
W6 = week 6, NC = negative control. 
 
5.8.3. Differentially regulated genes in PDGFRα-positive cells and control lung cells 
at P5 and W6 
 
Sequencing data from PDGFRα-positive and negative control lung cells were 
analyzed according to differentially expressed genes at postnatal day 5 (P5) and week 6 
(W6). Changes of gene expression levels (FPKM values) in different samples were 
presented as log2 (fold change); fold change>2, q<0.05. Number of differentially regulated 
genes was compared between W6 vs. P5, W6 vs. NC and P5 vs. NC (Figure 35A). Venn 
diagrams show 137 overlapping genes common for all three relationships, 909+137 
common for W6 vs. P5 and W6 vs. NC, 1170+137 common for W6 vs. P5 and P5 vs. NC, 
and 740+137 common for W6 vs. NC and P5 vs. NC (Figure 35A and B). Number of up- 
and down-regulated genes among each relationship is also shown (Figure 35C). 394 genes 
were up-regulated at both P5 and W6 compering to NC from which 75 were differentially 
regulated between P5 and W6 (Figure 35D). Only 6 of these 75 genes were up-regulated at 
P5 vs. W6 and remaining 69 at W6 vs. P5 (Appendix, Table A4). Based on criteria of 
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fibroblast structure, regulation of cell differentiation or septa formation, differentially 
expressed genes were selected and compared between W6 vs. P5, W6 vs. NC and P5 vs. 
NC (Figure 36); log2 (FC) values of these genes are shown in Appendix, Table A3.  Genes 
up-regulated at P5 vs. W6 (Figure 36A) were as follows: alpha smooth muscle actin 
(Acta2), elastin (Eln), myosin regulatory light polypeptide 7 and 9 (Myl7, 9), myosin heavy 
chain 11 (Myh11), smoothened (Smo), solute carrier family 27A6 (Slc27a6), sprouty 1 and 
4 (Spry1,4), types of collagen (Col), connective tissue growth factor (Ctgf), transforming 
growth factor beta 3 and 2 (Tgfb3, 2), transforming growth factor beta-induced (Tgfbi), 
transforming growth factor beta receptor 3 (Tgfbr3), and latent transforming growth factor 
beta binding protein 2, 3, 4 (Ltbp2, 3, 4). Genes down-regulated at P5 compared to W6 
were: coactosin-like protein (Cotl1), interleukin 17 receptor a (Il17ra), retinoid X receptor 
alpha (Rxra), peroxisome proliferator-activated receptor gamma (Pparγ), thymocyte 
differentiation antigen 1 (Thy1; CD90), lipoprotein lipase (Lpl), transforming growth factor 
beta receptor 1 and 2 (Tgfbr1, 2) and mir-29a. Platelet-derived growth factor receptor alpha 
(Pdgfrα) and platelet-derived growth factor receptor-like (Pdgfrl) were up-regulated at P5 
vs. W6 [log2 (2.72) and log2 (3.85), respectively]. Additionally, at W6 vs. NC most of the 
genes were down-regulated at W6 with the exception of: Cotl1, Il17ra, Pparγ, Lpl, Thy1, 
Tgfbi, Tgfbr1, mir-29a and mir-24-2 (Figure 36B). Pdgfrα was down-regulated at W6 vs. 
NC, whereas the expression at P5 was not significantly different compared to NC. Genes 
like Acta2, Myh11, Myl7, Cotl1, Slc27a6, Il17ra, Pdgfrl, Tgfbi, Ltbp2, mir-24-2 and 
another isoform of Col1a2 (this gene was not expressed at W6 and in NC) were up-
regulated at P5 vs. NC (Figure 36C). Two miRNA genes were specifically expressed at P5 
(significantly lower at W6 and not expressed in NC cells), i.e.:  mir-382 and mir-487b 
(Figure 36C). 
 
5.8.4. Gene set enrichment analysis of RNA-Seq dataset from PDGFRα-positive cells 
 
Gene set enrichment analysis (GSEA) was used to analyze differentially expressed 
gene sets in PDGFRα-positive cells at the time points P5 and W6. Two categories of gene 
sets were analyzed: gene sets involved in canonical pathways and gene sets sharing 3'-UTR 
microRNA binding motifs. Gene sets were considered as significantly different with a 
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FWER (Family-wise error rate) <0.05. The global overview on tested gene sets illustrates 
the total number of tested gene sets and their enrichment scores as well as significance and 
normalized enrichment scores (Figure 37A). For miRNA binding motifs we did not find a 
significantly different gene set for FWER<0.05 and FDR<0.25 at both P5 and W6 time 
points (Figure 37A, lower graph). Only 1 gene set (genes targeted by miR-155) was 
significantly enriched for p-value<0.05 at W6, while 9 gene sets (miR-137, -218, -522, -
196A, B, -422A, B, -489, -10A, B, -374, -384) were significantly enriched at P5. When it 
comes to gene sets related with canonical pathways, we found 13 gene sets to be enriched 
(FWER<0.05) at P5 (Figure 37B) and 70 at W6 (Figure 37C shows top 13 gene sets; 
Appendix, Table A5, remaining 57). Gene sets involved in ECM organization, collagen 
formation, muscle contraction, NCAM interactions, integrin1 pathway, cardiomyopathy, 
WNT and Hedgehog pathways signaling were significant for P5. Gene sets related with 
immunological system and immune system response regulation, infectious diseases, 
regulation of translation, and mRNA activation and metabolism were significant for W6. 
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Figure 35 Number of differentially regulated genes of PDGFRα-positive lung cells between W6 
vs. P5, W6 vs. NC and P5 vs. NC. Fold change (FC) cut-offs of >2 and significance for q-values of 
<0.05 were applied. A) Venn diagram of commonly differentially expressed genes among W6 vs. 
P5, W6 vs. NC and P5 vs. NC. B) Venn diagram of commonly differentially expressed  genes 
between separated two groups, W6 vs. NC and P5 vs. NC, W6 vs. NC and W6 vs. P5, P5 vs. NC and 
W6 vs. P5. C) Number of up- and down-regulated genes within each group. D) Genes up-regulated 
at both W6 and P5 compering to NC, and those of them differentially regulated between W6 and 
P5. NC = negative control, W6 = week 6 after birth, P5 = postnatal day 5.  
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Figure 36 Selected differentially regulated genes of PDGFRα-positive lung cells at P5, W6 and in 
NC. Genes were selected based on specific functions during lung development (see text above). Y-
axes show FPKM values as the transcripts abundance of specific genes differentially expressed 
between A) P5 vs. W6, B) W6 vs. NC and C) P5 vs. NC. q-value (FDR)<0.05, FC>2 cut-offs were 
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applied. FC = fold change, NC = negative control, W6 = week 6 after birth, P5 = postnatal day 5, 
FPKM = Fragments Per Kilobase of transcript per Million.  
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Enrichment plot for canonical pathway: FWER value NES 
Reactome: NCAM1 interactions <0.000 -2.71 
Reactome: Collagen formation <0.000 -2.62 
KEGG: Basal cell carcinoma <0.000 -2.56 
Reactome: ECM organization <0.002 -2.45 
KEGG: Dilated cardiomyopathy <0.006 -2.35 
KEGG: Hedgehog signaling pathway <0.006 -2.34 
PID: WNT signaling pathway <0.017 -2.28 
KEGG: Arrhythmogenic right ventricular 
cardiomyopathy ARVC 
<0.018 -2.28 
KEGG: ECM receptor interaction <0.018 -2.28 
PID: Integrin1 pathway <0.020 -2.27 
KEGG: Hypertrophic cardiomyopathy HCM <0.029 -2.24 
Reactome: muscle contraction <0.029 -2.24 
Reactome: NCAM signaling for neurite out growth <0.044 -2.21 
 
 
Enrichment plot for canonical pathway: FWER value NES 
KEGG: T cell receptor signaling pathway <0.000 2.81 
PID: IL12 pathway <0.000 2.77 
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KEGG: Natural killer cell mediated cytotoxicity <0.000 2.72 
REACTOME: Innate immune system <0.000 2.68 
KEGG: Primary immunodeficiency <0.000 2.68 
REACTOME: Immunoregulatory interactions between a 
lymphoid and a non lymphoid cell 
<0.000 2.65 
KEGG: Chemokine signaling pathway <0.000 2.63 
KEGG: Cytokine-cytokine receptor interaction <0.000 2.63 
PID: TCR pathway <0.000 2.62 
KEGG: Toll-like receptor signaling pathway <0.000 2.62 
REACTOME: Immune system <0.000 2.60 
PID: CD8 TCR pathway <0.000 2.59 
KEGG: B cell receptor signaling pathway <0.000 2.59 
 
Figure 37 Gene set enrichment analysis of the sequencing dataset obtained from PDGFRα-
positive cells RNA (P5 vs. W6). A) Plots show additional information about the gene sets and 
enrichment results performed for canonical pathways (CP) and miRNA binding motifs (miR). Left 
histograms show the number of gene sets enriched at P5 (negative ES values) and W6 (positive ES 
values). Right panels show a global statistics of significant and non-significant gene sets. Plots of 
nominal p-values and FDR q-values (y-axis) vs. NES (x-axis) are shown. B) and C) Gene sets as a 
representation of canonical biological processes at P5 (negative ES values) (B) and W6 (positive 
ES values) (C). Representative enrichment plots are shown for each time point. Green plots indicate 
an enrichment profile, where the peak indicates the ES for the gene set; black lines indicate the hits 
where the members of the gene set appear in the ranked list of genes (pink – genes encountered at 
W6; blue – genes encountered at P5). The top gene sets with the highest (W6) or lowest (P5) NES 
are shown in tables. NES= Normalized enrichment score, FWER= family-wise error rate, ES= 
enrichment score. References: [85]. Data was analyzed in collaboration with Dr. Mario Looso from 
Max Planck Institute in Bad Nauheim. 
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Chapter 6 
DISCUSSION 
 
In the present study we characterized the miRNome and transcriptome of a mouse 
lung PDGFRα-positive cells. This fibroblast subset has been shown to be strongly involved 
in lung development, in particular in myofibroblast differentiation during septum formation 
[13, 14]. These results provide insights into new putative target molecules whose control 
might be a useful tool to manipulate lung regeneration or develop new therapeutic 
approaches for structural lung diseases. 
 
6.1. Characterization of lung fibroblasts phenotype and localization in 
neonate and adult lung tissue 
 
In the first part of this study, we investigated localization and phenotype of three 
fibroblast subsets, the lipofibroblasts, the myofibroblast and PDGFRα-positive cells. All 
three fibroblast subtypes play a crucial role during rodent lung alveolarization. In particular 
the myofibroblasts have been demonstrated to be involved in the process of secondary 
septation and thus the formation of new alveoli [81, 127]. We showed that the fibroblast 
subsets phenotypic markers’ (ADRP, αSMA and PDGFRα) protein expression level 
decreases with the termination of alveolarization. Apoptosis of interstitial fibroblasts has 
been demonstrated to be one reason for this decrease in cell number [17, 102]. However the 
de-differentiation of fibroblasts subtypes might be a further reason [14]. Thus the regulation 
of the fibroblast phenotype plays a crucial role during lung development. Fibroblasts 
differentiation and proliferation need to be controlled in a tight and time-dependent manner. 
The myofibroblasts phenotypic marker, the α-smooth muscle actin (αSMA) protein and 
gene expression levels both peaked at postnatal day 10 as a consequence of “bulk 
alveolarization” process [19, 103]. However their expression was highly variable (at both 
protein and gene level) probably due to different developmental progress of the littermates 
used for cell isolation. The localization of myofibroblasts in the lung tissue was previously 
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well characterized. Their phenotypic markers, the αSMA or SMMHC are predominantly 
expressed at the tips of newly formed septa and around the alveolar rings during postnatal 
lung development [79]. However these two phenotypic markers are not exclusively specific 
for myofibroblast. They are also strongly expressed by smooth muscle cells surrounding 
bronchi/ bronchioles and blood vessels in neonate as well as in the adult lung. It has been 
shown that αSMA is regulated by different transcriptional mechanism in smooth muscle 
cells [39]. The slight changes of Pdgfrα gene expression levels at different lung 
developmental stages might suggest that its expression mainly is regulated on a post-
transcriptional level. Post-transcriptional regulation of PDGFRα expression was already 
proposed in rodent epididymis studies [8]. PDGFRα was localized in the alveolar 
interstitium, around the bronchi/ bronchioles but clearly it was not expressed by the 
epithelium, the endothelium and leukocytes. This is in line with previous studies which 
showed that PDGFRα-positive cells are localized at the ridge of newly formed septa 
enabling differentiation into myofibroblasts during the process of alveolarization [79].  
To get a clear picture of the fibroblast subsets phenotype, cells from whole lung 
homogenate were cultured at standard conditions and their differentiation capacity was 
investigated in detail. Fibroblasts obtained from neonatal animals had greater ability to 
differentiate into myofibroblasts than fibroblasts from adult mice. This observation was 
consistent with the fibroblast functionality in postnatal lung development. During this time, 
fibroblasts proliferate and differentiate to form new septa. These processes have to be 
tightly regulated by distinct molecular factors, which adjust the fibroblasts phenotype 
according to the requirements of the different lung developmental stages. In neonatal tissue 
fibroblasts are characterized by a “hyper-proliferative” phenotype whereas in adult healthy 
tissue they remain in a homeostatic “quiescent” phenotype. This in turn requires constant 
reprogramming of the fibroblasts phenotype and function which generally has been 
observed in cell culture [114]. Fibroblasts isolated from adult lung tissue differentiated into 
myofibroblasts, though they required more time for changing their phenotype than 
fibroblasts isolated from neonatal lung tissue. Therefore it is necessary to understand the 
mode of differentiation and the mechanisms leading to a change in phenotype of fibroblasts 
upon different requirements of physiological or pathophysiological processes. Against this 
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background, the molecular characterization of PDGFRα-positive fibroblasts is discusses in 
the following sections. 
 
6.2. PDGFRα expression level in lung tissue and cell culture 
 
The changes in phenotype and differentiation abilities of PDGFRα-positive cells 
were further investigated. The results showed that PDGFRα-positive cells (use of 
endogenous Pdgfrα gene tagged with GFP) are of mesenchymal origin and gain 
characteristics specific for myofibroblasts in cell culture. It has been shown that two 
different subsets of PDGFRα-positive cells are present in the lung, the dim and the bright 
[22, 55]. The “high-expressing” PDGFRα-GFP+ cells are associated with high expression 
of cytosolic αSMA, whereas “low-expressing” PDGFRα-GFP+ cells co-expressed αSMA 
on much lower level [55]. During lung development, the PDGFRα positive myofibroblasts 
are more resistant to apoptosis. [80]. Based on studies using the post-pneumonectomie re-
alveolarization model, Chen et al. hypothesized that the PDGFRα-GFPdim expression 
promotes the contractile function of fibroblasts, whereas the PDGFRα-GFPbright expression 
promotes synthesis of structural proteins (synthetic phenotype). Further, they stated that 
during lung development and regeneration, a balance between the contractile and the 
synthetic PDGFRα-positive fibroblast phenotypes must be maintained [22]. Using 
immunocytochemistry of cultured lung fibroblasts, isolated from the same transgenic 
mouse line, we showed that the signals of PDGFRα and αSMA were less stable than the 
ADRP signal during the period of cell culture. When cultured shortly (2h or 24h), 
PDGFRα-GFPbright+ cells were smaller and predominantly αSMA-negative but ADRP-
positive, when cultured longer (72h), the cells were PDGFRα-GFPdim+ and double αSMA-, 
ADRP- positive. Moreover, using cells from wild type mice, we showed that PDGFRαbright+ 
cells form long cytoplasmic extensions and may start to realize αSMA with high expression 
intensity what leads to new α-actin cytoskeleton formation. Thus, both αSMA and 
PDGFRα expression intensity decreased uniformly with myofibroblast cytoskeleton 
shaping. These data agree with the hypothesis of Chen et al.,; PDGFRα-GFPdim+ cells were 
characterized as differentiated homogenous myofibroblasts population, whereas PDGFRα-
GFP
bright+
 cells as undifferentiated fibroblasts with the ability to myofibroblasts 
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differentiation and ECM production. During lung development, the PDGFRαbright+ cells 
represent the majority of PDGFRα-positive cells. On the other hand, in adult mice we were 
still able to identify a small number of quiescent PDGFRαbright+ cells (FACSorting data). 
Thus, it may indicate that myofibroblasts differentiation and their cytoskeleton formation is 
strongly dependent on PDGFRα expression level regulation during lung development and 
in adulthood. 
 
6.3. MiRNA profiles of pulmonary PDGFRα-positive cells across different  
time points of lung development 
  
We aimed to understand the regulatory mechanisms which orchestrate the function 
and the phenotype of PDGFRα-positive fibroblast during lung septation and later in the 
adult tissue. To select the PDGFRα-positive cells from whole lung cells, we used magnetic 
beads/anti- PDGFRα antibody selection, thus only the cells with extracellularly exposed N-
terminal domain of the receptor were sorted. We chose four specific time points of lung 
development: E16.5, P5, P14 and W6. At E16.5 the process of alveolarization has not 
started yet while at W6 it is completed. In contrast, at P5 the alveolarization has just started, 
and at P14 alveoli are already formed and the process of microvascular maturation and 
thinning of septal interstitium occurs. Therefore, the postnatal day 5 was the most 
interesting time point to us, as at this time the major changes necessary for gas exchange 
units (alveoli) formation begin [19, 56, 92, 106]. Subsequently, we analyzed the miRNome 
of PDGFRα-positive fibroblast. It is known that miRNAs are the key regulators involved in 
many biological processes, such as apoptosis, differentiation and proliferation [26]. Using 
TaqMan low density arrays (TLDAs), we identified 98 miRNAs which were differentially 
expressed across the four time points. Moreover, these miRNAs could be split into specific 
clusters based on their similar expression patterns within the four time points. 56 of these 
miRNAs were up-regulated at P5 vs. W6 and only 16 miRNAs were up-regulated at W6 vs. 
P5. Previously it has been shown, that miRNAs may exhibit temporal and spatial cell type 
specific expression patterns and many of them are strongly involved and broadly regulated 
during lung development [11, 31] or lung diseases [123]. Indeed in our data miRNAs up-
regulated at postnatal day 5 were associated with developmental processes while at week 6 
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they were associated with the emergence of respiratory and connective tissue diseases or 
inflammatory response. Interestingly, there was no substantial difference between those 
two miRNA groups when it comes to regulation of the basic cell processes. It shows that 
during lung development and in adulthood, different miRNAs may act to confer accuracy 
and uniformity of the PDGFRα-positive cells phenotype and functions [35].  
To identify target genes of the miRNAs, we used some of the available online 
algorithm software which have been developed over the past few years [7]. This approach 
gave us helpful hints for further experiments. Using miRTarBase [50], we searched for the 
miRNAs validated to target the Pdgfrα gene. In our study none of these miRNAs was 
differentially regulated in PDGFRα-positive cells across the four time points of lung 
development. Nevertheless, we found 4 miRNAs up-regulated at P5 (miR-421, -449b, -149, 
-20b) which were predicted to target Pdgfrα 3’-UTR within its highly conserved sequence 
sites among vertebrates. Further miRNA bio-function analysis suggested that these 4 
miRNAs might be strongly implicated in regulation of fibroblast differentiation during 
alveolarization. However more information about these miRNAs is required. In vitro or in 
vivo functional studies would be the next step to investigate a gain or loss (use of mimics or 
inhibitors) of these miRNAs functions what simultaneously could prove their potential 
therapeutic application in lung interstitial diseases.  
Using miRTarBase [50], we searched for other miRNA candidates regulated in 
PDGFRα-positive cells, which are validated to target the genes that are involved in 
fibroblast subsets differentiation or ECM formation. We identified 2 miRNAs that are 
validated to target Tgfbr2 (miR-370-3p, -204-5p; both up-regulated at P5 vs. W6) [73, 120], 
1 validated to target Tgfb1 and 2 (miR-29b-3p; constant at P5 and W6) [75], 1 validated to 
target Pparγ (miR-20b-5p; also predicted to target Pdgfrα; up-regulated at P5 vs. W6) [45], 
2 validated to target elastin (miR-29a: down-regulated at P5 vs. W6 and miR-29b: constant 
at P5 vs. W6) [89, 118], and 3 validated to target different types of collagen (miR-29a, b, c; 
miR-29c: down-regulated at P5 vs. W6) [33, 44, 69, 118]. In fact, expression kinetics of all 
these miRNAs was opposite to the expression level of their target genes which analysis was 
performed based on our sequencing data. Hence, it is possible, that these miRNAs repress 
the expression of these genes. Further functional studies of these molecules (knock-down or 
overexpression) is needed to understand how these relationships are implicated in the 
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regulation of the process of alveolarization and the quiescent phenotype of fibroblasts in the 
adult lung.  
 
6.4. Differentially expressed genes of pulmonary PDGFRα-positive cells of 
postnatal and adult time points 
 
Next-generation sequencing was used to analyze the transcriptome of lung 
PDGFRα-positive cells and negative control obtained from postnatal day 5 and week 6 
mice. Using gene set information and canonical pathway analysis we identified gene 
candidates differentially regulated at P5 and W6. At P5 most of the genes were related with 
developmental processes and cellular function, whereas at W6 they were related with 
immunological response, cytokines signaling and transcription/translation regulation. 
Similarly, analysis of differentially regulated genes between P5 vs. W6, P5 vs. NC and W6 
vs. NC showed that all the genes responsible for myofibroblasts differentiation and the 
synthetic phenotype (ECM components production), such as Acta2, Myh11, types of Myl, 
Pdgfrα, Pdgfrl, types of Col, Eln, Ctgf, Tgfbi, Tgfb2, 3, types of Ltbp and Tgfbr3 were 
down-regulated in the PDGFRα-positive cells obtained at W6 vs. P5. Most of these genes 
were previously reported and closely investigated. It has been shown that TGFβ induces 
differentiation of lung fibroblasts into myofibroblasts and it is implicated in the 
pathogenesis of pulmonary fibrosis [62]. Another gene, Tgfbi was highly up-regulated at 
both P5 and W6 comparing to NC, and it was log2 (1.18)-fold change higher at P5 vs. W6. 
The Tgfbi gene encodes the extracellular matrix (ECM) attachment protein which contains 
an RGD (DNA recognition sequence) site. It binds to the type I, II and IV collagens (cell-
collagen interactions) and serves as a ligand recognition sequence for several integrins [87]. 
Thus it seems to be necessary for the cell-matrix interactions, cell adhesion, migration and 
differentiation during the process of alveolarization. Additionally, two miRNA genes i.e. 
mir-487b and mir-382 were up-regulated at P5 vs. NC and significantly down-regulated at 
W6 vs. P5 according to our data obtained by the use of the TLDA method. Validated gene 
targets and functions of these two miRNAs are still not well characterized. Recent studies 
showed that cigarette smoke mediates epigenetic repression of miR-487b during human 
pulmonary carcinogenesis (study based on epithelial cell culture) and revealed its 5 direct 
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targets: SUZ12, BMI1, WNT5A, MYC, and KRAS [125]. Whereas miR-382 contributes to 
renal inner medullary interstitial fibrosis in a mouse model and it targets kallikrein 5 (Klk5) 
[60]. Thus, these two miRNAs could be an interesting indication for further functional 
studies of the lung during development or disease models.  
Our data suggest that the gene profile of PDGFRα-positive cells isolated from W6 
mouse lungs is more characteristic for the lipofibroblast phenotype rather than the 
myogenic phenotype. Cells isolated from W6 lung tissue were characterized by the higher 
expression of following genes: Pparγ, Rxra, Thy1, Lpl (all four genes were previously 
reported as lipofibroblasts markers), Cotl1 and mir-29a. It has been shown that THY-1 
signals through PPARγ/RXRa to promote lipofibroblast differentiation during lung 
development [77, 78, 108, 119] and antagonizes the fibrogenic processes, like cell 
differentiation, inflammation and wound healing as well as myofibroblast differentiation 
[18, 64, 98, 119]. On the other hand, we showed that fibrogenic Tgfβr1 and 2 were also up-
regulated at W6 vs. P5. However, their activation might be inhibited by PPARγ signaling 
via a Smad-independent pathway [62]. Substantial up-regulation of mir-29a at W6 vs. P5 
was also consistent with our data obtained by the use of TLDA. Mir-29a might have an 
crucial effect on elastin [89, 118] and collagen [33] negative regulation, whereas coactosin-
like protein (Cotl1; actin-binding protein) might negatively regulate F-actin cytoskeleton 
formation in myofibroblasts [32, 93].  
Previous multiple studies showed that the pulmonary lipofibroblasts are THY1+ 
PPARγ+ and number of these cells increases at the onset of alveolarization [3], however 
not all of the lipofibroblasts are THY1
+ 
[119]. In contrast, our data showed that Thy1, Rxra 
and Pparγ genes expression level was up-regulated after lung development termination, i.e. 
in adulthood rather than in neonate. Thy1 gene expression pattern from our data was 
consistent with previous observations, showing that in rodent lung tissue homogenate the 
THY1
+ 
cell number increases at P5 and then even more in adult [119]. In spite of this, 
THY1
+
 cells might not play a critical role in the surfactant production. It has been shown 
that Thy1 knockout mouse pups do not exhibit surfactant deficiency or respiratory distress 
syndrome [119]. Furthermore, Adrp was not found to be differentially expressed between 
P5, W6 and even NC. Previously it has been shown that ADRP is essential for many 
metabolic processes of different cell types, like macrophages, cultured epithelial cells or 
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within tissue by lactating mammary epithelial cells [46, 95]. Therefore, the ADRP might 
not be a perfect marker for lipofibroblasts like thought before [94, 104]. In our studies, the 
ADRP protein expression level was significantly up-regulated (~2.5-fold change) in whole 
lung tissue homogenate at P5 vs. adult (W8). Its expression level might be decreased due to 
the apoptosis of fibroblasts after the alveolarization process termination. On the other hand, 
the solute carrier family 27A6 (Slc27a6; membrane transport protein) responsible for fatty 
acid transport was log2 (4.06)-fold change higher at P5 vs. W6. This finding supports the 
concept that fatty-acid transporter proteins might mediate increased fatty-acid uptake 
necessary for surfactant production during alveolarization [119]. Furthermore, our data 
suggest that THY1 and PPARγ signaling pathway may have a crucial role in PDGFRα-
positive cells differentiation regulation in adulthood. Increased Thy1 and Pparγ gene 
expression might negatively influence myofibroblast phenotype induction by delaying 
PDGFRα activation or antagonizing Pdgfrα gene expression [22].   
Our data showed that Pdgfrα gene expression level was log2 (2.7) down-regulated 
at W6 vs. P5 and log2 (2.2) down-regulated at W6 vs. NC. It was not 2-fold change 
different at P5 vs. NC. This fact was striking since PDGFRα-positive cells were selected 
via anti-PDGFRα antibody positive selection and negative control cells via anti-PDGFRα 
antibody negative selection. One explanation might be that in the negative control the 
present cell types (presumably it could be already existing number of myofibroblasts or 
smooth muscle cells) did not express PDGFRα at the cell surface, but significant Pdgfrα 
gene expression might have led to intracellular protein expression which was post-
transcriptionally regulated or the PDGFRα protein was recycled or antagonized. These 
findings are supported by the fact, that numerous types of negative regulatory mechanism 
of RTKs have been already proposed, i.e. the ligand and receptor availability, regulation of 
downstream signaling components or of the respective transcription factors, post-
transcriptional regulation or the receptor endocytosis (receptor recycling or degradation) 
[20]. Abundance of unstimulated tyrosine kinase receptors (RTK) at the cell surface may be 
controlled via production and continuous recycling. Interactions between cytoskeletal 
components and the plasma membrane may also affect receptor distribution and signaling 
by forming cytosolic corral traps (compartmentalization of receptor within the plasma 
membrane). Additionally, it has been shown that RTK signaling is not only limited to the 
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cell surface, but can continue within the endocytic compartment [20]. As mentioned before, 
PDGFRα is the receptor responsible for conducting signals necessary for basic biological 
function of the cell, ranging from cell migration and survival to proliferation and 
differentiation. Therefore, it must be under tight spatial regulation enabling tissue 
morphogenesis and function during lung development. However it remains unsolved how 
exactly the receptor signaling is regulated. We already showed that 4 miRNAs (miR-421, -
449b, -149, -20b) which are highly expressed by PDGFRα-positive cells at P5 might 
putatively target the Pdgfrα 3’-UTR within its highly conserved sites. This could be one of 
the possible post-transcriptional regulatory mechanisms of Pdgfrα gene expression during 
development. Furthermore, previously a large number of inhibitory proteins that act to 
attenuate the signals originating from activated RTK receptors have been identified. These 
specific proteins are working as negative feedback loop mechanisms and can be present 
prior to the receptor activation or are transcriptionally induced upon the receptor 
stimulation in the cell. One of these proteins called Sprouty (SPRY) is transcriptionally 
activated and later phosphorylated by RTK signaling. Sproutys are known inhibitors of 
fibroblast growth factor (FGF) signaling and play an essential role in lung branching 
morphogenesis [43]. However, only SPRY4 (but not SPRY1 and SPRY2) phosphorylation 
can be induced by FGF, EGF, and PDGF [111]. Our data showed that two gene members of 
the Spry family were up-regulated at P5 comparing to W6 and down-regulated at W6 
comparing to NC. The Spry4 expression level was log2 (2.34)-fold change and Spry1 log2 
(2.65)-fold change higher at P5 vs. W6, while Spry4 was log2 (2.90)-fold change and Spry1 
log2 (2.39)-fold change lower at W6 vs. NC. These findings show that the Spry genes 
expression level was elevated consistently with Pdgfrα gene expression level in PDGFRα-
positive cells isolated from P5 mice and in NC. In turn, this suggests the involvement of a 
negative feedback loop regulatory mechanism of the Pdgfrα gene at P5 but not W6. Likely, 
the low expression level of the Pdgfrα gene at W6 might be an effect of PPARγ-dependent 
regulation and in consequence the lack of PDGFRα protein activation might induce a 
dispensable function of the Spry genes. Higher expression level of Pparγ gene at W6 could 
also have an effect on the activation of Spry4 expression. In the same line Tennis, et al. 
showed that Spry4 expression level is regulated by PPARγ signaling outside of the RTK 
pathway [111]. Analysis of PDGFRα-positive cells gene and miRNA expression profiles 
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allowed us to identify putative molecular mechanisms involved in PDGFRα-positive 
fibroblasts regulation and myofibroblasts differentiation that vary in neonate and adulthood.  
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Chapter 7 
CONCLUSIONS 
 
Pulmonary PDGFR-positive fibroblasts have been shown to obtain a high 
plasticity and capacity to differentiation into specialized fibroblasts subtypes during the 
process of alveolar septation. But the underlying regulatory mechanisms still remain 
unknown. Furthermore a variety of molecular switches might be involved in the signaling 
during alveolar septation. Since pulmonary structural diseases are characterized by a loss or 
destruction of the alveolar structures, a better understanding of these molecular mechanisms 
driving alveolar septum formation might help to discover novel targets for therapeutic 
regenerative approaches.  Therefore the present study aimed to compare the molecular 
profile at the miRNome and transcriptome level of PDGFR-positive fibroblasts at 
different time points of lung development  
The identification of lung PDGFRα-positive fibroblast specific miRNA expression 
profiles revealed a distinct number of relevant candidates. In particular, 98 miRNAs were 
identified and characterized by different expression patterns across four time points of lung 
development. 56 of these miRNAs were up-regulated at P5 vs. W6 and only 16 miRNAs at 
W6 vs. P5, whereas the remaining miRNAs were expressed at the same level at P5 and W6. 
In silico analysis of these miRNAs revealed more insight into PDGFRα-positive fibroblasts 
function and phenotype during alveolarization. Next-generation sequencing supported our 
data from the miRNA analysis and disclosed further relevant gene candidates. 
Transcriptome data analysis showed that PDGFRα-positive cells molecular phenotype and 
differentiation abilities highly differ during the onset of alveolarization, and later in 
adulthood.  
In conclusion, we discovered relevant miRNA and gene candidates which represent 
the first basis for further loss- or gain-of-function studies to identify new therapeutic targets 
for structural lung diseases. 
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Figure 38 Schematic picture of PDGFRα-positive fibroblasts phenotype and their differentiation 
capacity at postnatal day 5 (P5) and week 6 (W6). Arrows indicate the level of differentially 
expressed genes (up↑, down↓). In the boxes, genes differentially up-regulated at a specific stage of 
cell differentiation or time point are shown. “+” indicates activated PDGF Receptor α signaling, 
“-” indicates lack of the activation. A) At P5, the PDGFRα-positive fibroblasts differentiate into 
myofibroblasts and produce ECM (Col= collagen, Eln= elastin). Hypothetical phenotype of 
differentiated myofibroblast is shown (*). B) At W6 the PDGFRα-positive fibroblasts do not 
differentiate into myofibroblast and remain in quiescent mode. Myofibroblasts and smooth muscle 
cells (SMCs) differentiated during late lung development are still present at W6 (“existing SMC, 
myofibroblast”). Hypothetical phenotype of myofibroblast and SMC is shown (*). 
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ABSTRACT 
BACKGROUND AND AIM The process of alveolarization is tightly regulated and 
requires the contribution of different subpopulations of fibroblasts such as myofibroblasts, 
lipofibroblasts and platelet-derived growth factor receptor α (PDGFRα)-positive 
fibroblasts. Each of this fibroblasts subset fulfills certain functions during lung 
development in a time-dependent manner. In particular PDGFRα-positive cells are crucial 
for alveolar septation and myofibroblasts differentiation. PDGF-A deletion in vivo leads to 
a disruption of septum formation in mice. Therefore, we aimed to characterize PDGFRα-
positive fibroblasts specific miRNA and mRNA expression profiles at different time points 
of lung development. We hypothesized that their phenotype, differentiation capacities and 
functions might be regulated by the change of expression profiles during the different 
stages of lung development and homeostasis.  
RESULTS Lung PDGFRα-positive fibroblasts were isolated using magnetic beads/anti-
PDGFRα antibody positive selection. Using TaqMan low density array analysis we 
identified 98 significantly regulated miRNAs out of 750 tested miRNAs that exhibited 
different expression patterns across four time points of lung development. 56 of these 
miRNAs were up-regulated at P5 vs. W6 and only 16 miRNAs at W6 vs. P5. In silico 
analysis of these miRNA candidates allowed us to identify their function and gene targets. 
Subsequent analysis of the PDGFRα-positive fibroblasts transcriptome using next-
generation sequencing revealed gene candidates differentially regulated during 
alveolarization and in adulthood.  
CONCLUSIONS MiRNome and transcriptome dataset analysis showed that the molecular 
phenotype and functions of pulmonary PDGFRα-positive cells greatly differ during the 
onset of alveolarization, and later in adulthood. Simultaneously, we identified relevant 
miRNAs and gene candidates which might serve as a basis for “loss or gain of function” 
analysis. These functional studies are essential to identify new therapeutic targets for 
structural lung diseases and regenerative medicine. 
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ZUSAMMENFASSUNG 
 
HINTERGRUNDINFORMATION und ZIEL Der Prozess der Alveolarisierung 
unterliegt einer strengen Regulation. Verschiedene Subpopulationen pulmonaler 
Fibroblasten wie beispielsweise Myofibroblasten, Lipofibroblasten und platelet-derived 
growth factor receptor α (PDGFRα)-positive Fibroblasten sind daran beteiligt. Jeder dieser 
Fibroblasten Subtypen vollbringt eine zeitabhängige bestimmte Funktion während der 
Lungenentwicklung. Insbesondere tragen PDGFRα-positive Zellen wesentlich zu der 
Septenbildung und der Differenzierung von Myofibroblasten bei. In vivo Deletion von 
PDGF-A führt zu einer Störung der Alveolarisierung in Mäusen. Daher liegt das Ziel der 
vorliegenden Arbeit darin, miRNA- und mRNA-Expressionsprofile PDGFRα-positiver 
Fibroblasten, zu verschiedenen Zeitpunkten der Lungenentwicklung zu bestimmen. Die 
Hypothese der vorliegenden Arbeit besteht darin, dass der Phänotyp, die 
Differenzierungsmöglichkeiten und die Funktionen PDGFRα-positiver Fibroblasten durch 
eine Änderung der Expressionsprofile zu verschiedenen Zeitpunkten der 
Lungenentwicklung und Homöostase reguliert werden. 
ERGEBNISSE PDGFRα positive Fibroblasten der Lunge wurden durch Magnetseparation 
und positiv Selektion mittels Antikörper gegen PDGFRα isoliert. Die miRNome-Analyse 
der PDGFRα-positiven Fibroblasten an vier verschiedenen Zeitpunkten der 
Lungenentwicklung durch TaqMan low density array ergab 98 statistisch signifikant 
regulierte miRNAs von 750 analysierten miRNAs. 56 dieser miRNAs zeigten sich hoch-
reguliert an P5 vs. W6 und nur 16 miRNAs an W6 vs. P5. In silico Analysen dieser miRNA 
Kandidaten ermöglichte es, ihre Funktionen und Zielgene zu identifizieren. Die Analyse 
des Transcriptoms PDGFRα-positiver Fibroblasten durch “next-generation sequencing” 
erbrachte Gen Kandidaten deren Expression während der Alveolarisierung im Vergleich zu 
der adulten Lunge unterschiedlich reguliert war. 
SCHLUSSFOLGERUNG Die miRNome und Transcriptome Datenanalyse zeigte, dass 
sich der molekulare Phänotyp und die Funktionen von PDGFRα-positiven Zellen zwischen 
dem Beginn der Alveolarisierung und später der adulten Lunge sehr stark unterscheiden. 
Gleichzeitig wurden relevante miRNAs und Gen Kandidaten identifiziert, die als 
Ansatzpunkt  für „loss“ oder „gain of function” Analysen dienen können. Diese 
funktionellen Studien sind erforderlich, um therapeutisch relevante Zielmoleküle für die 
regenerative Therapie von Lungengerüsterkrankungen zu identifizieren. 
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ABBREVIATIONS 
°C – Celsius degree 
µg – microgram 
µl – microliter 
µm – micrometer 
AGCT – adenine, guanine, cytosine, thymine 
Asp – aspartic acid 
bp – base pair 
BSA – bovine serum albumin 
CCD – charge-coupled device 
CD – cluster differentiation 
cDNA – complementary deoxynucleic acid 
cm – centimeter 
CO2 – carbon dioxide 
CreER – tamoxifen-dependent (binds to estrogen receptor (ER)) Cre recombinase 
Cy3 – cyanine 3 
DAPI – 4',6-diamidino-2-phenylindole 
ddATP – 2',3'-Dideoxyadenosine-5'-Triphosphate 
ddCTP – 2',3'-Dideoxycytidine-5'-Triphosphate 
ddGTP – 2',3'-Dideoxyguanosine-5'-Triphosphate 
ddH2O – double distilled water 
ddTTP – 2',3'-Dideoxythymidine-5'-Triphosphate 
DNA – deoxynucleic acid 
DNase – deoxynuclease 
EDTA – ethylenediaminetetraacetic acid 
eGFP – enhance green fluorescent protein 
FITC – fluorescein isothiocyanate  
Gb – giga base pairs 
gDNA – genomic deoxynucleic acid 
h – hour 
H2B – histone H2B 
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HCl – hydrochloric acid 
His – histidine 
IgG – immunoglobulin G 
kDa – kilodalton 
KH2PO4 – potassium dihydrogen phosphate 
KHCO3 – potassium bicarbonate 
loxP – locus of X-over P1 is a site on the Bacteriophage P1 consisting of 34 bp 
M – molar 
min – minute 
ml – milliliter 
mM – milimolar 
mRNA – messenger ribonucleic acid 
Na2HPO4 ∙ 2H2O – disodium phosphate dihydrate  
NaCl – sodium Chloride 
NH4Cl – ammonium chloride 
nt – nucleotide 
PBS – phosphate buffered saline 
PCR – polymerase chain reaction  
PFA – paraformaldehyde 
pH – hydrogen ion concentration 
qPCR – quantitative polymerase chain reaction 
RNA – ribonucleic acid 
rpm – revolutions per minute 
rRNA – ribosomal ribonucleic acid 
RT – room temperature 
SD – standard deviation 
SDS – sodium dodecyl sulfate 
SDS-PAGE – sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TAE – tris-acetate-EDTA 
TaqMan – Taq Polymerase + PacMan = TaqMan 
TBST – tris-buffered saline and tween 20 
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TEMED – tetramethylethylenediamine 
UNG – uracil N-glycosylase 
UV – ultraviolet 
V – volt 
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APPENDIX 
 
 
Figure A1 Isotype control of immunofluorescent staining in cell culture. Wild type (WT) or GFP-
tagged mouse lung cells were stained with mouse IgG/Cy3, rat IgG or rabbit IgG primary 
antibodies and Alexa Fluor 488 or 555 secondary antibodies. Scale bar = 30 or 100µm. 
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Figure A2 Isotype control of immunofluorescent staining in lung tissue. Wild type (WT) or GFP-
tagged mice lung tissue slides were stained with anti-GFP/FITC, mouse IgG, rat IgG or rabbit IgG 
primary antibodies and Alexa Fluor 488 or 555 secondary antibodies. Scale bar = 50µm. 
 
Table A1 Affiliation of miRNAs into miRNA families based on the same seed region 
sequence. According to IPA. 
CLUSTER miRNAs miRNA family w/in seed CLUSTER miRNAs miRNA family w/in seed 
Cluster 0 mmu-miR-666-5p miR-666-5p w/seed GCGGGCA Cluster15 
 
mmu-miR-370 
mmu-miR-433 
 mmu-miR-434-5p 
mmu-miR-495 
mmu-miR-337 
mmu-miR-487b 
mmu-miR-541 
mmu-miR-543 
rno-miR-350 
rno-miR-551B 
miR-370-3p w/seed CCUGCUG 
miR-433-3p w/seed UCAUGAU 
miR-434-5p w/seed CUCGACU 
miR-495-3p w/seed AACAAAC 
miR-337-3p w/seed UCAGCUC 
miR-487b-3p w/seed AUCGUAC 
miR-541-5p w/seed AGGGAUU 
miR-543-3p w/seed AACAUUC 
miR-350 w/seed UCACAAA 
miR-551b-3p w/seed GCGACCC 
Cluster2 mmu-miR-543 
mmu-miR-299 
mmu-miR-376a* 
mmu-miR-673-3p 
miR-543-3p w/seed AACAUUC 
N/A 
miR-376a-5p w/seed GUAGAUU)  
miR-673-3p w/seed CCGGGGC 
Cluster16 
 
mmu-miR-30d 
mmu-miR-146a 
mmu-miR-146b 
mmu-miR-150 
mmu-miR-222 
mmu-miR-29a 
rno-miR-146B 
miR-30c-5p w/seed GUAAACA 
miR-146a-5p w/seed GAGAACU 
miR-146a-5p w/seed GAGAACU 
miR-150-5p w/seed CUCCCAA 
miR-221-3p w/seed GCUACAU 
miR-29b-3p w/seed AGCACCA 
miR-146a-5p w/seed GAGAACU 
Cluster 4 hsa-miR-421 
mmu-miR-1939 
mmu-miR-674* 
miR-421-3p w/seed UCAACAG 
N/A 
miR-674-3p w/seed ACAGCUC 
Cluster 17 mmu-miR-369-5p miR-369-5p w/seed GAUCGAC 
Cluster5 
 
mmu-miR-323-3p 
mmu-miR-410 
mmu-miR-130b* 
mmu-miR-376b* 
mir-323-3p w/seed ACAUUAC 
miR-344d-3p w/seed AUAUAAC 
miR-130b-5p w/seed CUCUUUC 
miR-376b-5p w/seed UCAUAGA 
Cluster18 
 
mmu-miR-126-3p 
mmu-miR-223 
hsa-miR-200c 
hsa-miR-223 
miR-126-3p w/seed CGUACCG 
miR-223-3p w/seed GUCAGUU 
miR-200b-3p w/seed AAUACUG 
miR-223-3p w/seed GUCAGUU 
Cluster6 mmu-miR-805 N/A Cluster19 
 
mmu-miR-127 
mmu-miR-193b 
mmu-miR-296-5p 
mmu-miR-335-3p 
mmu-miR-335-5p 
rno-miR-351 
mmu-miR-411 
hsa-miR-149 
miR-127-3p w/seed CGGAUCC 
miR-193a-3p w/seed ACUGGCC 
miR-296-5p w/seed GGGCCCC 
miR-335-3p w/seed UUUUCAU 
miR-335-5p w/seed CAAGAGC 
miR-125b-5p w/seed CCCUGAG 
N/A 
miR-149-5p w/seed CUGGCUC 
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Table A2 Nomenclature of genes or encoded proteins inside the miRNA networks 
generated by IPA. 
Dicer1  Dcr-1 homolog  Tp53 Tumor protein p53 
Ssb Sjögren's syndrome antigen B (autoantigen La) E2f3 
E2f2 
E2f1 
E2F transcription factor 3 
E2F transcription factor 2 
E2F transcription factor 1 
Dcp2 mRNA-decapping enzyme 2 Ventx VENT homeobox 
Ago2 Argonaute RISC catalytic component 2 Clpb Caseinolytic peptidase B protein homolog 
Nr0b2 nuclear receptor subfamily 0, group B, member 
2 
Ctnnb1 β-catenin (cadherin-associated protein) 
Esrrg Estrogen-related receptor gamma Crebl2 (CRE)-binding protein-like-2 
Ddx20 DEAD (Asp-Glu-Ala-Asp) box polypeptide 20 Inppl1  Inositol polyphosphate phosphatase-like 1 
Zic1 Zic Family Member 1 Dusp9 Dual specificity phosphatase 9 
 
    hsa-miR-93* 
mmu-miR-1839-3p 
mmu-miR-322* 
mmu-miR-322 
mmu-miR-503* 
rno-miR-20b 
miR-93-3p w/seed CUGCUGA 
miR-1839-3p w/seed GACCUAC 
miR-322-3p w/seed AACAUGA 
N/A 
miR-503-3p w/seed AGUAUUG 
miR-17-5p w/seed AAAGUGC 
Cluster 7 
 
mmu-miR-29c 
mmu-miR-139-5p 
mmu-miR-155 
mmu-miR-34c* 
rno-miR-664 
miR-29b-3p w/seed AGCACCA 
miR-139-5p w/seed CUACAGU 
miR-155-5p w/seed UAAUGCU 
miR-34c-3p w/seed AUCACUA 
miR-664-3p w/seed AUUCAUU 
Cluster20 
 
mmu-miR-126-5p 
mmu-miR-92a 
hsa-miR-200b 
mmu-miR-374-5p 
miR-126-5p w/seed AUUAUUA 
miR-92a-3p w/seed AUUGCAC 
miR-200b-3p w/seed AAUACUG 
miR-374b-5p w/seed UAUAAUA 
Cluster 8 mmu-miR-451 miR-451a w/seed AACCGUU Cluster 22 
 
mmu-miR-204 
mmu-miR-376a 
mmu-miR-376b 
hsa-miR-206 
miR-204-5p w/seed UCCCUUU 
miR-376a-3p w/seed UCGUAGA 
miR-376a-3p w/seed UCAUAGA 
miR-1w/seed GGAAUGU 
Cluster 9 mmu-miR-1904 miR-1904 w/seed UUCUGCU Cluster24 mmu-miR-463 N/A 
Cluster 10 
 
mmu-miR-135b 
mmu-miR-376c 
mmu-miR-379 
mmu-miR-382 
mmu-miR-409-3p 
mmu-miR-434-3p 
hsa-miR-214* 
hsa-miR-455 
mmu-miR-449b 
rno-miR-409-3P 
Y1 
miR-135a-5p w/seed AUGGCUU 
miR-376c-3p w/seed ACAUAGA 
miR-379-5p w/seed GGUAGAC 
miR-382-5p w/seed AAGUUGU 
miR-409-3p w/seed AAUGUUG 
miR-434-3p w/seed UUGAACC 
mir-214-5p w/seed GCCUGUC 
miR-455-5p w/seed AUGUGCC 
mir-34a-5p w/seed GGCAGUG 
miR-409a-3p  w/seed AUGUUGC 
N/A 
Cluster25 
 
mmu-miR-29b 
mmu-miR-23a 
mmu-miR-1931 
mmu-miR-1943 
miR-29b-3p w/seed AGCACCA 
miR-23a-3p w/seed UCACAUU 
miR-1931 w/seed UGCAAGG 
miR-1321 w/seed AGGGAGG 
Cluster13 mmu-miR-375 
mmu-miR-532-3p 
miR-375-3p w/seed UUGUUC 
miR-532-3p w/seed CUCCCAC 
Cluster27 mmu-miR-205 
mmu-miR-423-5p 
miR-205-5p w/seed CCUUCAU 
miR-423-5p w/seed GAGGGGC 
Cluster14 
 
mmu-miR-329 
rno-miR-758 
rno-miR-219-1-3p 
hsa-miR-154* 
 mmu-miR-1199  
mmu-miR-483* 
mmu-miR-483 
mmu-miR-879* 
miR-329-3p w/seed ACACACC 
miR-758-3p w/seed UUGUGAC 
miR-219a-1-3p w/seed GAGUUGC 
miR-154-3p w/seed AUCAUACN/A 
miR-1199-5p w/seed CUGAGUCN/A 
miR-483-3p w/seed CACUCCU 
N/A 
miR-879-3p w/seed CUUAUGG 
Cluster 28 hsa-miR-28-3p 
mmu-miR-31* 
miR-28-3p w/seed ACUAGAU 
miR-31-3p w/seed GCUAUGC 
 
   Cluster 29 
 
mmu-miR-668 
hsa-miR-136 
rno-miR-379* 
rno-miR-382* 
miR-668-3p w/seed GUCACUC 
miR-136-5p w/seed CUCCAUU 
miR-379-3p w/seed UAUGUAA 
N/A 
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Cdkn1b Cyclin-dependent kinase inhibitor 1B (p27, 
Kip1) 
Gprc6a G protein-coupled receptor, family C, group 6, 
member A 
Cdk7 
Cdk5 
Cdk4 
Cyclin-dependent kinase 7 
Cyclin-dependent kinase 5 
Cyclin-dependent kinase 4 
Smad2/
3 
Smad7 
SMAD family member 2 and 3 complex 
SMAD family member 7 
Map2k1/2 
 
Map4k4  
 
Mapk14 
Dual specificity mitogen-activated protein 
kinase kinase 1/2 
Mitogen-activated protein kinase kinase kinase 
kinase 4 
Mitogen-activated protein kinase 14 
Lin28A Lin-28 homolog A 
Pik3ca Phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha 
Sgca Sarcoglycan, alpha (50kDa dystrophin-
associated glycoprotein) 
Tgfb1 Transforming growth factor beta 1 Rps15 Ribosomal protein S15 
Aqp4 Aquaporin 4 Ins1 Insulin I 
Fhod1 Formin homology 2 domain containing 1 Ccna2 
Ccne1 
Ccnd1 
Ccnd2 
Cyclin A2 
Cyclin E1 
Cyclin D1 
Cyclin D2 
Erk Extracellular signal-regulated kinases Rb1 Retinoblastoma 1 
Msmb Microseminoprotein, beta Fsh Follicle-stimulating hormone 
Pdlim3 PDZ and LIM domain 3 Notch1 NOTCH1 
Klf4 Kruppel-like factor 4 H2afx H2A histone family, member X 
Sirt1 Sirtuin 1 Runx2 Runt-related transcription factor 2 
Atf3 Activating transcription factor 3 Psen1 Presenilin 1 
Bcl2 B-cell CLL/lymphoma 2 Dhfr Dihydrofolate reductase 
Mcm3 Minichromosome maintenance complex 
component 3 
Tgfbr2 Transforming growth factor, beta receptor II 
Met Mesenchymal-epithelial transition factor Ptpre Protein tyrosine phosphatase, receptor type, E 
Ppara Peroxisome proliferator-activated receptor 
alpha 
Creb cAMP response element-binding protein 
Tsc1 Tuberous sclerosis 1 Ikbip IKBKB interacting protein 
Birc5 Baculoviral IAP repeat containing 5 Chuk Conserved helix-loop-helix ubiquitous kinase 
Il-8 Interleukin 8 Ctgf Connective tissue growth factor 
Bdnf Brain-derived neurotrophic factor Cfl1 Cofilin 1 
Acta2 F-actin Cg Cancer-germline 
Mapre2 Microtubule-associated protein, RP/EB family, 
member 2 
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Table A3 Differentially regulated genes of PDGFRα-positive cells at different time points. 
Length (bp) of transcript isoforms, log2 (fold change) of FPKM and q-values are shown. 
Colors indicate the log2 (FC) of transcript expression level up-regulated at P5, W6 or in 
NC; blue = up-regulated at W6, orange = up-regulated at P5, green = up-regulated in NC. 
999.0 = infinity (transcript not expressed in one condition) bp = base pair, FC = fold 
change, NC = negative control, W6 = week 6, P5 = postnatal day 5. “-” = not differentially 
regulated. 
Gene Length (bp) 
log2(FC) W6 vs. P5 
(q value) 
log2(FC) W6 vs. NC 
(q value) 
log2(FC) P5 vs. NC 
(q value) 
Pdgfrα 6553 2.7 (0.002) 2.2 (0.001) - 
Pdgfrl 1548 3.8 (0.008) - -2.0 (0.008) 
Acta2 1781 3.39 (0.002) 2.07 (0.001) -1.36 (0.008) 
Eln 3950 3.15 (0.002) - - 
Myh11 6593 3.89 (0.002) 2.06 (0.007) -1.87 (0.02) 
Myl6 665 - 1.54 (0.04) 2.24 (0.01) 
Myl7 590 1.70 (0.02) - -2.94 (0.02) 
Myl9 1128 3.32 (0.002) 2.79 (0.001) - 
Cotl1 1520 -1.50 (0.002) -3.46 (0.001) -1.99 (0.002) 
Il17ra 3970 -2.02 (0.002) -3.46 (0.001) -1.47 (0.006) 
Pparg 1857 -2.24 (0.03) -3.02 (0.01) - 
Rxra 4905 -1.46 (0.01) - - 
Lpl 1900 -2.70 (0.002) -3.05 (0.001) - 
Thy1 1735 -3.17 (0.002) -4.18 (0.001) - 
Slc27a6 2485 4.09 (0.002) - -2.93 (0.002) 
Spry1 2451 2.65 (0.002) 2.39 (0.003) - 
Spry4 4587 2.34 (0.002) 2.90 (0.001) - 
Col15a1 5172 1.61 (0.02) - - 
Col1a2 5346 2.57 (0.002) 2.30 (0.02) - 
I Col1a2 5318 - - -999.00 (0.03) 
Col12a1 11511 2.74 (0.002) 1.96 (0.001) - 
Col3a1 5564 2.17 (0.02) 2.89 (0.03) - 
Col5a2 6625 2.63 (0.002) 2.85 (0.001) - 
Col4a4 10018 1.94 (0.003) - - 
Col1a1 5933 2.76 (0.01) - - 
Col6a2 3949 2.36 (0.002) 2.25 (0.001) - 
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Col4a5 6536 - 2.47 (0.01) - 
Col6a1 4100 1.78 (0.002) 2.26 (0.001) - 
Col23a1 5658 2.08 (0.002) 2.12 (0.04) - 
Ctgf 2398 1.80 (0.002) 1.92 (0.001) - 
Smo 3779 2.72 (0.002) 2.86 (0.001) - 
Tgfbi 2678 1.18 (0.02) -4.03 (0.001) -5.24 (0.002) 
Tgfb2 4725 4.15 (0.02) - - 
Tgfb3 3384 3.30 (0.01) 2.94 (0.05) - 
Tgfbr1 5756 -1.91 (0.002) -1.56 (0.01) - 
Tgfbr2 8013 -1.79 (0.04) - - 
Tgfbr3 6087 1.55 (0.002) 1.67 (0.001) - 
Tgfa 3762 - 1.94 (0.01) 1.81 (0.05) 
Ltbp2 6769 4.28 (0.002) 2.29 (0.001) -2.03 (0.01) 
Ltbp3 5190 2.75 (0.002) 1.77 (0.01) - 
Ltbp4 5118 1.54 (0.002) 2.81 (0.01) - 
Mir-24-2 9585 - -1.47 (0.02) -1.31 (0.03) 
Mir-487b 452 - - -999.00 (0.01) 
Mir-382 477 - - -999.00 (0.02) 
Mir-29a 10026 -3.50 (0.002) -3.79 (0.001) - 
Mir-30a 10175 1.58 (0.05) - - 
 
Table A4 Genes up-regulated in PDGFRα-positive cells at P5 vs. NC and W6 vs. NC, and 
those of them differentially regulated between P5 vs. W6. The length (bp) of transcript 
isoforms, log2 (fold change) of FPKM and q-values are shown. Positive numbers indicate 
the log2 (FC) of transcript expression level up-regulated at P5 and negative numbers at W6; 
bp = base pair, FC = fold change, W6 = week 6, P5 = postnatal day 5, NC = negative 
control. 
Gene Length (bp) log2(FC) W6 vs. P5 q value  
Stfa1 439 4.1 0.02 
H19 2286 1.99 0.000 
Kntc1 6961 1.32 0.000 
Per2 5835 1.19 0.04 
Tgfbi 2678 1.18  0.02 
Hist1h2bj 463 1.02  0.02 
Golm1 3557 -1.04  0.01 
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Lcn2 915 -1.07  0.01 
Parp8 3088 -1.08  0.01 
Lrp12 4095 -1.17 0.000 
Mfsd7c 3435 -1.18 0.000 
Tnfrsf21 3626 -1.24 0.000 
Ramp1 2549 -1.32 0.000 
Gm12867 12926 -1.34 0.01 
Cx3cr1 3729 -1.4 0.000 
Cotl1 1520 -1.5 0.000 
Itga4 9767 -1.71 0.000 
Pygl 2825 -1.77 0.000 
Il1a 1974 -1.92 0.000 
Itgal 5194 -1.96 0.000 
Sirpa 3637 -1.98 0.000 
Fpr1 1324 -1.98 0.000 
Il17ra 3970 -2.02 0.000 
Csf2rb 4764 -2.03 0.000 
1600029D21Rik 1846 -2.04 0.000 
Fcer1g 674 -2.06 0.000 
Plcg2 4296 -2.15 0.000 
Syk 5122 -2.21 0.01 
Lsp1 1395 -2.22 0.000 
Ccl6 1440 -2.31 0.000 
Tlr2 3013 -2.31 0.000 
Ccdc21 3128 -2.34 0.000 
Mrc1 5352 -2.34 0.000 
Pld4 1978 -2.34 0.000 
Marco 1985 -2.35 0.000 
Cyfip2 6298 -2.35 0.000 
Stk10 5026 -2.36 0.000 
Nckap1l 4717 -2.36 0.000 
Rac2 3036 -2.36 0.000 
Ctss 1355 -2.37 0.000 
Tyrobp 564 -2.4 0.000 
Mpeg1 4335 -2.41 0.000 
Cybb 4752 -2.46 0.000 
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Ccdc88b 4959 -2.5 0.000 
1810033B17Rik 1132 -2.61 0.000 
Ptafr 3637 -2.62 0.000 
Cxcl2 1080 -2.65 0.000 
Ear1 713 -2.65 0.000 
Atp6v0d2 2539 -2.69 0.000 
Itgb2 2970 -2.71 0.000 
Ccl6 776 -2.72 0.000 
Cd53 2802 -2.75 0.000 
Clec7a 2205 -2.79 0.000 
Niacr1 1938 -2.82 0.000 
AI504432 8892 -2.82 0.000 
Card11 4112 -2.83 0.000 
Dock2 6409 -2.92 0.000 
Il1b 1356 -2.96 0.000 
S100a8 392 -2.98 0.000 
Ptprc 4609 -3.01 0.000 
Cxcl2 1830 -3.06 0.000 
Cd14 1572 -3.11 0.000 
Gp49a 5396 -3.3 0.000 
Trem1 3024 -3.45 0.000 
 
Table A5 Gene sets enrichment for canonical pathways analysis for W6 time point. 
Normalized enrichment score (NES) and family-wise error rate (FWER) values are shown. 
GSEA was used, references: [85]. 
Canonical Pathway NES FWER value  
REACTOME: Chemokine receptors bind chemokines  2.59 0.000 
REACTOME: Cytokine signaling in immune system  2.57 0.000 
KEGG: Hematopoietic cell lineage  2.56 0.000 
REACTOME: Costimulation by the CD28 family  2.55 0.000 
REACTOME: Signaling by ILs  2.53 0.000 
REACTOME: Influenza viral RNA transcription and replication  2.52 0.000 
REACTOME: Translation  2.52 0.000 
REACTOME: Peptide chain elongation  2.48 0.000 
REACTOME: SRP dependent cotranslational protein targeting to 2.48 0.000 
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membrane 
REACTOME: Influenza life cycle  2.46 0.001 
REACTOME: 3’ UTR mediated translational regulation 2.46 0.001 
PID: IL12 STAT4 pathway  2.46 0.001 
KEGG: Lysosome  2.45 0.001 
REACTOME: Nonsense mediated decay enhanced by the exon junction 
complex  
2.44 0.001 
PID: BCR 5 pathway  2.44 0.001 
KEGG: Intestinal immune network for IGA production  2.44 0.001 
KEGG: Ribosome  2.43 0.001 
PID: NFAT TF pathway 2.41 0.001 
REACTOME: Toll receptor cascades  2.39 0.001 
REACTOME: TCR signaling 2.35 0.002 
REACTOME: Interferon alpha beta signaling  2.34 0.002 
KEGG: NOD-like receptor signaling pathway  2.34 0.002 
BIOCARTA: NO2 IL12 pathway  2.33 0.005 
KEGG: Apoptosis  2.32 0.005 
KEGG: Leishmania infection 2.32 0.005 
KEGG: JAK STAT signaling pathway  2.32 0.005 
REACTOME: Metabolism of mRNA  2.31 0.005 
REACTOME: Generation of second messenger molecules  2.31 0.005 
BIOCARTA: CTLA4 pathway  2.31 0.005 
BIOCARTA: T helper pathway  2.30 0.005 
PID: PI3KCI pathway 2.29 0.005 
PID: CD8 TCR downstream pathway  2.28 0.006 
REACTOME: Nucleotide binding domain leucine rich repeat 
containing receptor NLR signaling pathway  
2.26 0.006 
REACTOME: Signaling by the B cell receptor BCR  2.25 0.007 
REACTOME: Metabolism of RNA  2.25 0.008 
BIOCARTA: T cytotoxic pathway  2.24 0.008 
KEGG: Antigen processing and presentation  2.23 0.009 
PID: HIV NEF pathway   2.23 0.009 
REACTOME: Interferon signaling  2.22 0.009 
ST: T cell signal transduction  2.21 0.011 
KEGG: FC epsilon ri signaling pathway  2.19 0.018 
REACTOME: Activated TLR4 signaling  2.19 0.018 
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BIOCARTA: Stem pathway  2.19 0.019 
KEGG: Graft versus host disease  2.18 0.021 
REACTOME: Adaptive immune system  2.18 0.021 
KEGG: RIG I-like receptor signaling pathway  2.16 0.027 
REACTOME: PD1 signaling  2.15 0.029 
REACTOME: Interferon gamma signaling  2.15 0.029 
SIG: BCR signaling pathway  2.15 0.029 
REACTOME: Activation of the mRNA upon binding of the Cap 
binding complex and EIFS and subsequent binding to 43S  
2.15 0.031 
BIOCARTA: NKT pathway 2.13 0.042 
REACTOME: GPVI-mediated activation cascade  2.13 0.042 
BIOCARTA: DC pathway 2.13 0.043 
PID: REG GR pathway  2.13 0.044 
PID: IL4 2 pathway  2.12 0.046 
REACTOME: MYD88 MAL cascade initiated on plasma membrane  2.12 0.047 
REACTOME: IL- 3, -5 and GM-CSF signaling  2.12 0.049 
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